arsonic acid - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	arsonic acid	go back to main search page
Accession:	CHEBI:29850	browse the term
Definition:	A member of the arsonic acids that has formula AsH3O3.
Synonyms:	exact_synonym:	hydridodihydroxidooxidoarsenic
	related_synonym:	Formula=AsH3O3; H2AsHO3; InChI=1S/AsH3O3/c2-1(3)4/h1H,(H2,2,3,4); InChIKey=BUSBFZWLPXDYIC-UHFFFAOYSA-N; SMILES=[H][As](O)(O)=O; [AsHO(OH)2]
	xref:	Gmelin:2037439
	cyclic_relationship:	is_conjugate_acid_of CHEBI:64448

show annotations for term's descendants Sort by:
Rat (634) Mouse (751) Human (656) Chinchilla (0) Bonobo (0) Dog (0) Squirrel (0) Pig (0) Green Monkey (0) Naked Mole-rat (0) All
Genes (656)

arsanilic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

brain derived neurotrophic factor

multiple interactions
decreases expression

Dexamethasone inhibits the reaction [Arsanilic Acid results in decreased expression of BDNF mRNA]; Dexamethasone inhibits the reaction [Arsanilic Acid results in decreased expression of BDNF protein]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [Arsanilic Acid results in decreased expression of BDNF mRNA]]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [Arsanilic Acid results in decreased expression of BDNF protein]]
Arsanilic Acid results in decreased expression of BDNF mRNA; Arsanilic Acid results in decreased expression of BDNF protein

NCBI chr11:27,654,893...27,722,030
Ensembl chr11:27,654,893...27,722,058

G

caspase 3

increases activity
increases expression
increases cleavage
multiple interactions

Arsanilic Acid results in increased activity of CASP3 protein
Arsanilic Acid results in increased expression of CASP3 mRNA
Arsanilic Acid results in increased cleavage of CASP3 protein
Dexamethasone inhibits the reaction [Arsanilic Acid results in increased cleavage of CASP3 protein]; Dexamethasone inhibits the reaction [Arsanilic Acid results in increased expression of CASP3 mRNA]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [Arsanilic Acid results in increased cleavage of CASP3 protein]]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [Arsanilic Acid results in increased expression of CASP3 mRNA]]

PMID:23848144 PMID:30628712

NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062

G

caspase 9

increases activity

Arsanilic Acid results in increased activity of CASP9 protein

NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534

G

neurotrophic receptor tyrosine kinase 2

multiple interactions
decreases expression

Dexamethasone inhibits the reaction [Arsanilic Acid results in decreased expression of NTRK2 mRNA]; Dexamethasone inhibits the reaction [Arsanilic Acid results in decreased expression of NTRK2 protein]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [Arsanilic Acid results in decreased expression of NTRK2 mRNA]]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [Arsanilic Acid results in decreased expression of NTRK2 protein]]
Arsanilic Acid results in decreased expression of NTRK2 mRNA; Arsanilic Acid results in decreased expression of NTRK2 protein

NCBI chr 9:84,668,522...85,027,054
Ensembl chr 9:84,668,375...85,095,751

G

solute carrier family 12 member 5

multiple interactions
decreases expression

Dexamethasone inhibits the reaction [Arsanilic Acid results in decreased expression of SLC12A5 mRNA]; Dexamethasone inhibits the reaction [Arsanilic Acid results in decreased expression of SLC12A5 protein]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [Arsanilic Acid results in decreased expression of SLC12A5 mRNA]]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [Arsanilic Acid results in decreased expression of SLC12A5 protein]]
Arsanilic Acid results in decreased expression of SLC12A5 mRNA; Arsanilic Acid results in decreased expression of SLC12A5 protein

NCBI chr20:46,021,686...46,060,150
Ensembl chr20:46,021,690...46,060,150

methylarsonic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

alpha-2-macroglobulin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of A2ML1 mRNA

NCBI chr12:9,067,708...9,116,229
Ensembl chr12:9,067,664...9,116,229

G

acetoacetyl-CoA synthetase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of AACS mRNA

NCBI chr12:125,065,435...125,143,316
Ensembl chr12:125,065,434...125,143,333

G

alanine and arginine rich domain containing protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of AARD mRNA

NCBI chr 8:116,938,207...116,944,487
Ensembl chr 8:116,938,207...116,944,487

G

ATP binding cassette subfamily B member 1

increases expression

monomethylarsonic acid results in increased expression of ABCB1A mRNA; monomethylarsonic acid results in increased expression of ABCB1A protein

NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323

G

ATP binding cassette subfamily C member 1 (ABCC1 blood group)

increases expression
affects expression

monomethylarsonic acid results in increased expression of ABCC1 mRNA; monomethylarsonic acid results in increased expression of ABCC1 protein
monomethylarsonic acid affects the expression of ABCC1 mRNA

PMID:16436460 PMID:24091636

NCBI chr16:15,949,143...16,143,053
Ensembl chr16:15,949,138...16,143,257

G

ATP binding cassette subfamily C member 2

increases expression

monomethylarsonic acid results in increased expression of ABCC2 mRNA; monomethylarsonic acid results in increased expression of ABCC2 protein

PMID:16436460 PMID:24091636

NCBI chr10:99,782,640...99,852,594
Ensembl chr10:99,782,640...99,852,594

G

ATP binding cassette subfamily C member 3

increases expression

monomethylarsonic acid results in increased expression of ABCC3 mRNA; monomethylarsonic acid results in increased expression of ABCC3 protein

NCBI chr17:50,634,881...50,692,253
Ensembl chr17:50,634,777...50,692,253

G

ArfGAP with coiled-coil, ankyrin repeat and PH domains 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ACAP1 mRNA

NCBI chr17:7,336,529...7,351,477
Ensembl chr17:7,336,529...7,351,477

G

acyl-CoA thioesterase 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ACOT1 mRNA

NCBI chr14:73,490,933...73,543,796
Ensembl chr14:73,537,143...73,543,796

G

acyl-CoA thioesterase 12

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ACOT12 mRNA

NCBI chr 5:81,308,609...81,394,134
Ensembl chr 5:81,329,996...81,394,179

G

acyl-CoA oxidase 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ACOX2 mRNA

NCBI chr 3:58,505,136...58,537,190
Ensembl chr 3:58,505,136...58,537,283

G

acrosin binding protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ACRBP mRNA

NCBI chr12:6,638,075...6,647,432
Ensembl chr12:6,638,075...6,647,433

G

ADAM metallopeptidase with thrombospondin type 1 motif 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ADAMTS4 mRNA

NCBI chr 1:161,184,302...161,199,054
Ensembl chr 1:161,184,302...161,199,054

G

ADAM metallopeptidase with thrombospondin type 1 motif 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ADAMTS6 mRNA

NCBI chr 5:65,148,738...65,481,920
Ensembl chr 5:65,148,738...65,481,920

G

adhesion G protein-coupled receptor G1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ADGRG1 mRNA

NCBI chr16:57,619,738...57,665,567
Ensembl chr16:57,610,652...57,665,580

G

adrenomedullin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ADM mRNA

NCBI chr11:10,305,073...10,307,397
Ensembl chr11:10,305,073...10,307,397

G

adrenoceptor alpha 2B

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ADRA2B mRNA

NCBI chr 2:96,112,876...96,116,571
Ensembl chr 2:96,112,876...96,116,571

G

adrenoceptor beta 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ADRB1 mRNA

NCBI chr10:114,043,866...114,046,904
Ensembl chr10:114,043,866...114,046,904

G

adrenoceptor beta 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ADRB2 mRNA

NCBI chr 5:148,826,611...148,828,623
Ensembl chr 5:148,826,611...148,828,623

G

ALF transcription elongation factor 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of AFF3 mRNA

NCBI chr 2:99,545,419...100,142,590
Ensembl chr 2:99,545,419...100,192,428

G

alpha fetoprotein

increases expression

monomethylarsonic acid results in increased expression of AFP mRNA

NCBI chr 4:73,436,221...73,456,174
Ensembl chr 4:73,431,138...73,456,174

G

anterior gradient 3, protein disulphide isomerase family member

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of AGR3 mRNA

NCBI chr 7:16,854,681...16,881,983
Ensembl chr 7:16,859,412...16,881,987

G

AT-hook DNA binding motif containing 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of AHDC1 mRNA

NCBI chr 1:27,534,245...27,604,227
Ensembl chr 1:27,534,035...27,604,431

G

aryl hydrocarbon receptor

multiple interactions

AHR mutant form inhibits the reaction [monomethylarsonic acid results in increased expression of CYP1A1 protein]; monomethylarsonic acid results in decreased expression of and affects the localization of AHR protein

NCBI chr 7:17,298,652...17,346,147
Ensembl chr 7:16,916,359...17,346,152

G

adenylate kinase 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of AK4 mRNA

NCBI chr 1:65,147,552...65,232,145
Ensembl chr 1:65,147,549...65,232,145

G

aldo-keto reductase family 7 member A2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of AKR7A5 mRNA

NCBI chr 1:19,302,708...19,312,146
Ensembl chr 1:19,303,965...19,312,144

G

AKT serine/threonine kinase 1

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of AKT1 mRNA

NCBI chr14:104,769,349...104,795,748
Ensembl chr14:104,769,349...104,795,751

G

aldolase, fructose-bisphosphate C

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ALDOC mRNA

NCBI chr17:28,573,120...28,576,895
Ensembl chr17:28,573,115...28,576,948

G

alpha kinase 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ALPK1 mRNA

NCBI chr 4:112,297,369...112,442,621
Ensembl chr 4:112,285,509...112,442,621

G

angiopoietin like 7

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ANGPTL7 mRNA

NCBI chr 1:11,189,355...11,195,981
Ensembl chr 1:11,189,355...11,195,981

G

ankyrin repeat domain 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ANKRD1 mRNA

NCBI chr10:90,912,096...90,921,087
Ensembl chr10:90,912,096...90,921,087

G

ANKRD40 C-terminal like

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ANKRD40CL mRNA

NCBI chr17:50,761,030...50,767,518
Ensembl chr17:50,761,029...50,767,557

G

annexin A8

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ANXA8 mRNA

NCBI chr10:47,467,993...47,991,796
Ensembl chr10:47,460,162...47,484,158

G

apolipoprotein L4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of APOL9A mRNA

NCBI chr22:36,189,128...36,204,833
Ensembl chr22:36,189,124...36,204,840

G

amphiregulin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of AREG mRNA

NCBI chr 4:74,445,136...74,455,005
Ensembl chr 4:74,445,136...74,455,005

G

Rho GTPase activating protein 15

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ARHGAP15 mRNA

NCBI chr 2:143,129,419...143,768,352
Ensembl chr 2:143,091,362...143,768,352

G

Rho GTPase activating protein 25

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ARHGAP25 mRNA

NCBI chr 2:68,710,544...68,826,833
Ensembl chr 2:68,679,601...68,826,833

G

Rho GTPase activating protein 30

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ARHGAP30 mRNA

NCBI chr 1:161,046,946...161,069,891
Ensembl chr 1:161,046,946...161,069,970

G

Rho GTPase activating protein 45

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ARHGAP45 mRNA

NCBI chr19:1,065,959...1,086,628
Ensembl chr19:1,065,923...1,086,628

G

Rho GTPase activating protein 8

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ARHGAP8 mRNA

NCBI chr22:44,752,575...44,862,784
Ensembl chr22:44,752,558...44,862,788

G

Rho GDP dissociation inhibitor beta

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ARHGDIB mRNA

NCBI chr12:14,942,015...14,961,601
Ensembl chr12:14,942,031...14,961,728

G

Rho guanine nucleotide exchange factor 38

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ARHGEF38 mRNA

NCBI chr 4:105,552,620...105,682,566
Ensembl chr 4:105,552,620...105,708,093

G

ADP ribosylation factor like GTPase 5C

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ARL5C mRNA

NCBI chr17:39,156,732...39,166,161
Ensembl chr17:39,156,894...39,167,484

G

ADP ribosylation factor like GTPase 9

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ARL9 mRNA

NCBI chr 4:56,505,209...56,524,453
Ensembl chr 4:56,505,209...56,524,959

G

arsenite methyltransferase

increases metabolic processing
increases expression
multiple interactions
increases chemical synthesis

AS3MT protein polymorphism results in increased metabolism of monomethylarsonic acid; AS3MT protein results in increased metabolism of monomethylarsonic acid
monomethylarsonic acid results in increased expression of AS3MT protein
[AS3MT gene polymorphism affects the susceptibility to Arsenic] which results in increased abundance of monomethylarsonic acid; [AS3MT protein polymorphism results in increased metabolism of arsenite] which results in increased chemical synthesis of monomethylarsonic acid; [AS3MT protein polymorphism results in increased metabolism of monomethylarsonic acid] which results in increased chemical synthesis of Cacodylic Acid; [AS3MT protein polymorphism results in increased metabolism of monomethylarsonic acid] which results in increased chemical synthesis of dimethylarsinous acid; [AS3MT protein results in increased metabolism of arsenite] which results in increased chemical synthesis of monomethylarsonic acid; [AS3MT protein results in increased metabolism of monomethylarsonic acid] which results in increased chemical synthesis of Cacodylic Acid; [AS3MT protein results in increased metabolism of monomethylarsonic acid] which results in increased chemical synthesis of dimethylarsinous acid
AS3MT protein results in increased chemical synthesis of monomethylarsonic acid

PMID:22005461 PMID:22868225 PMID:24845704 PMID:36399430

NCBI chr10:102,869,470...102,901,899
Ensembl chr10:102,869,470...102,901,899

G

ankyrin repeat and SOCS box containing 14

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ASB14 mRNA

NCBI chr 3:57,268,342...57,292,685
Ensembl chr 3:57,268,342...57,292,685

G

ankyrin repeat and SOCS box containing 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ASB4 mRNA

NCBI chr 7:95,470,656...95,551,317
Ensembl chr 7:95,478,444...95,540,233

G

aspartic peptidase retroviral like 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ASPRV1 mRNA

NCBI chr 2:69,932,717...70,087,375
Ensembl chr 2:69,960,089...69,961,631

G

activating transcription factor 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ATF3 mRNA

NCBI chr 1:212,565,407...212,620,777
Ensembl chr 1:212,565,334...212,620,777

G

activating transcription factor 7 interacting protein 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ATF7IP2 mRNA

NCBI chr16:10,386,061...10,483,638
Ensembl chr16:10,326,434...10,483,638

G

ATPase phospholipid transporting 10D (putative)

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ATP10D mRNA

NCBI chr 4:47,485,275...47,593,486
Ensembl chr 4:47,485,275...47,593,486

G

ATPase copper transporting beta

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ATP7B mRNA

NCBI chr13:51,932,669...52,012,132
Ensembl chr13:51,930,436...52,012,125

G

beta-1,3-galactosyltransferase 5

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of B3GALT5 mRNA

NCBI chr21:39,612,940...39,673,137
Ensembl chr21:39,556,442...39,673,137

G

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of B3GNT5 mRNA

NCBI chr 3:183,253,253...183,273,385
Ensembl chr 3:183,253,253...183,298,504

G

B cell scaffold protein with ankyrin repeats 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of BANK1 mRNA

NCBI chr 4:101,790,730...102,074,812
Ensembl chr 4:101,411,286...102,074,812

G

BTG3 associated nuclear protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of BANP mRNA

NCBI chr16:87,949,238...88,077,318
Ensembl chr16:87,949,244...88,077,318

G

BCL6 corepressor like 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of BCORL1 mRNA

NCBI chr X:129,980,313...130,058,071
Ensembl chr X:129,981,107...130,058,071

G

bifunctional apoptosis regulator

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of BFAR mRNA

NCBI chr16:14,632,951...14,669,236
Ensembl chr16:14,632,931...14,669,236

G

basic helix-loop-helix family member e41

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of BHLHE41 mRNA

NCBI chr12:26,120,030...26,125,037
Ensembl chr12:26,120,030...26,125,037

G

BLK proto-oncogene, Src family tyrosine kinase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of BLK mRNA

NCBI chr 8:11,494,387...11,564,599
Ensembl chr 8:11,486,894...11,564,599

G

basic helix-loop-helix ARNT like 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of BMAL1 mRNA

NCBI chr11:13,276,652...13,387,266
Ensembl chr11:13,276,652...13,387,266

G

BRI3 binding protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of BRI3BP mRNA

NCBI chr12:124,993,645...125,051,167
Ensembl chr12:124,993,645...125,031,231

G

Bruton tyrosine kinase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of BTK mRNA

NCBI chr X:101,349,450...101,390,796
Ensembl chr X:101,349,338...101,390,796

G

B and T lymphocyte associated

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of BTLA mRNA

NCBI chr 3:112,463,966...112,499,624
Ensembl chr 3:112,463,966...112,499,472

G

chromosome 19 open reading frame 38

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of AB124611 mRNA

NCBI chr19:10,836,685...10,869,790
Ensembl chr19:10,836,575...10,869,790

G

C1q and TNF related 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of C1QTNF3 mRNA

NCBI chr 5:34,017,858...34,244,724
Ensembl chr 5:34,017,858...34,043,213

G

calcium voltage-gated channel subunit alpha1 I

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CACNA1I mRNA

NCBI chr22:39,570,753...39,689,735
Ensembl chr22:39,570,753...39,689,735

G

calcium/calmodulin dependent protein kinase IG

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CAMK1G mRNA

NCBI chr 1:209,583,714...209,613,939
Ensembl chr 1:209,583,714...209,613,939

G

calpain 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CAPN3 mRNA

NCBI chr15:42,359,501...42,412,317
Ensembl chr15:42,359,498...42,412,949

G

caspase recruitment domain family member 11

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CARD11 mRNA

NCBI chr 7:2,906,142...3,043,867
Ensembl chr 7:2,906,142...3,044,228

G

capping protein regulator and myosin 1 linker 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CARMIL2 mRNA

NCBI chr16:67,645,144...67,657,569
Ensembl chr16:67,644,988...67,657,569

G

caspase 3

affects response to substance
multiple interactions
increases expression

CASP3 protein affects the susceptibility to monomethylarsonic acid
[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of CASP3 mRNA
monomethylarsonic acid results in increased expression of CASP3 mRNA
[monomethylarsonic acid co-treated with Buthionine Sulfoximine] results in increased activity of CASP3 protein

PMID:15963344 PMID:17481689 PMID:23192986

NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,650,062

G

catalase

multiple interactions

[CAT protein results in decreased oxidation of monomethylarsonous acid] which results in decreased chemical synthesis of monomethylarsonic acid

NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060

G

cation channel sperm associated 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of CATSPER4 mRNA

NCBI chr 1:26,190,602...26,202,964
Ensembl chr 1:26,190,561...26,202,968

G

coiled-coil domain containing 122

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CCDC122 mRNA

NCBI chr13:43,819,018...43,879,740
Ensembl chr13:43,823,909...43,879,740

G

coiled-coil domain containing 162, pseudogene

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CCDC162 mRNA

NCBI chr 6:109,165,831...109,354,948
Ensembl chr 6:109,183,955...109,355,046

G

coiled-coil domain containing 71 like

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of CCDC71L mRNA

NCBI chr 7:106,654,360...106,661,158
Ensembl chr 7:106,654,360...106,661,158

G

coiled-coil domain containing 78

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CCDC78 mRNA

NCBI chr16:722,582...726,880
Ensembl chr16:722,582...726,954

G

coiled-coil domain containing 87

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CCDC87 mRNA

NCBI chr11:66,590,176...66,593,063
Ensembl chr11:66,590,176...66,593,063

G

coiled-coil domain containing 92B

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CCDC92B mRNA

NCBI chr17:2,720,801...2,749,652
Ensembl chr17:2,720,801...2,749,652

G

C-C motif chemokine ligand 22

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CCL22 mRNA

NCBI chr16:57,357,909...57,366,189
Ensembl chr16:57,358,783...57,366,189

G

cellular communication network factor 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of CCN1 mRNA

NCBI chr 1:85,580,761...85,583,950
Ensembl chr 1:85,580,761...85,584,589

G

cyclin D1

increases expression

monomethylarsonic acid results in increased expression of CCND1 mRNA

NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474

G

cyclin E1

increases expression

monomethylarsonic acid results in increased expression of CCNE1 mRNA

NCBI chr19:29,811,991...29,824,312
Ensembl chr19:29,811,991...29,824,312

G

C-C motif chemokine receptor 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CCR6 mRNA

NCBI chr 6:167,111,795...167,139,141
Ensembl chr 6:167,111,807...167,139,141

G

C-C motif chemokine receptor 7

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CCR7 mRNA

NCBI chr17:40,553,769...40,565,472
Ensembl chr17:40,553,769...40,565,472

G

CD180 molecule

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD180 mRNA

NCBI chr 5:67,179,613...67,196,799
Ensembl chr 5:67,179,613...67,196,799

G

CD2 molecule

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD2 mRNA

NCBI chr 1:116,754,430...116,769,229
Ensembl chr 1:116,754,430...116,769,229

G

CD22 molecule

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD22 mRNA

NCBI chr19:35,329,187...35,347,361
Ensembl chr19:35,319,261...35,347,361

G

CD28 molecule

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD28 mRNA

NCBI chr 2:203,706,482...203,738,912
Ensembl chr 2:203,706,475...203,738,912

G

CD37 molecule

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD37 mRNA

NCBI chr19:49,335,406...49,340,606
Ensembl chr19:49,335,171...49,343,335

G

CD40 molecule

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD40 mRNA

NCBI chr20:46,118,314...46,129,858
Ensembl chr20:46,118,271...46,129,863

G

CD46 molecule

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD46 mRNA

NCBI chr 1:207,752,038...207,795,516
Ensembl chr 1:207,752,037...207,795,513

G

CD5 molecule

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD5 mRNA

NCBI chr11:61,093,963...61,127,852
Ensembl chr11:61,102,489...61,127,852

G

CD52 molecule

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD52 mRNA

NCBI chr 1:26,317,958...26,320,523
Ensembl chr 1:26,317,958...26,320,523

G

CD53 molecule

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD53 mRNA

NCBI chr 1:110,871,210...110,899,922
Ensembl chr 1:110,871,188...110,899,922

G

CD6 molecule

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD6 mRNA

NCBI chr11:60,971,680...61,020,377
Ensembl chr11:60,971,680...61,020,377

G

CD69 molecule

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD69 mRNA

NCBI chr12:9,752,486...9,760,901
Ensembl chr12:9,752,486...9,760,901

G

CD79a molecule

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD79A mRNA

NCBI chr19:41,877,279...41,881,372
Ensembl chr19:41,877,279...41,881,372

G

CD79b molecule

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD79B mRNA

NCBI chr17:63,928,740...63,932,331
Ensembl chr17:63,928,738...63,932,336

G

CD83 molecule

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD83 mRNA

NCBI chr 6:14,117,256...14,136,918
Ensembl chr 6:14,117,256...14,136,918

G

CD84 molecule

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD84 mRNA

NCBI chr 1:160,541,098...160,579,496
Ensembl chr 1:160,541,095...160,579,516

G

CD86 molecule

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD86 mRNA

NCBI chr 3:122,055,362...122,121,136
Ensembl chr 3:122,055,362...122,121,139

G

cell division cycle 25B

decreases activity

monomethylarsonic acid results in decreased activity of CDC25B protein

NCBI chr20:3,786,951...3,806,115
Ensembl chr20:3,786,772...3,806,121

G

CDC42 effector protein 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of CDC42EP2 mRNA

NCBI chr11:65,314,866...65,322,417
Ensembl chr11:65,314,866...65,322,417

G

cadherin 1

increases expression

monomethylarsonic acid results in increased expression of CDH1 mRNA

NCBI chr16:68,737,292...68,835,537
Ensembl chr16:68,737,292...68,835,537

G

cadherin 2

increases expression

monomethylarsonic acid results in increased expression of CDH2 mRNA

NCBI chr18:27,932,879...28,177,130
Ensembl chr18:27,932,879...28,177,946

G

cyclin dependent kinase 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of CDK3 mRNA

NCBI chr17:76,000,855...76,005,998
Ensembl chr17:76,000,855...76,005,999

G

cyclin dependent kinase like 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CDKL1 mRNA

NCBI chr14:50,326,265...50,397,298
Ensembl chr14:50,326,265...50,416,461

G

cyclin dependent kinase inhibitor 1A

decreases expression
multiple interactions

monomethylarsonic acid results in decreased expression of CDKN1A mRNA
[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of CDKN1A mRNA

PMID:17481689 PMID:23192986

NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,337

G

CECR2 histone acetyl-lysine reader

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CECR2 mRNA

NCBI chr22:17,359,949...17,558,151
Ensembl chr22:17,359,949...17,558,151

G

cilia and flagella associated protein 47

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CFAP47 mRNA

NCBI chr X:35,919,734...36,385,317
Ensembl chr X:35,919,734...36,385,317

G

chondroadherin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of CHAD mRNA

NCBI chr17:50,464,496...50,468,880
Ensembl chr17:50,464,496...50,468,906

G

cysteine and histidine rich domain containing 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of CHORDC1 mRNA

NCBI chr11:90,200,429...90,223,049
Ensembl chr11:90,200,429...90,223,077

G

cholinergic receptor nicotinic alpha 9 subunit

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of CHRNA9 mRNA

NCBI chr 4:40,335,333...40,355,217
Ensembl chr 4:40,335,333...40,355,217

G

carbohydrate sulfotransferase 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CHST3 mRNA

NCBI chr10:71,964,395...72,013,558
Ensembl chr10:71,964,395...72,013,558

G

circadian associated repressor of transcription

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CIART mRNA

NCBI chr 1:150,282,554...150,287,093
Ensembl chr 1:150,282,543...150,287,093

G

class II major histocompatibility complex transactivator

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CIITA mRNA

NCBI chr16:10,866,206...10,943,021
Ensembl chr16:10,866,222...10,943,021

G

cartilage intermediate layer protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CILP mRNA

NCBI chr15:65,194,760...65,211,473
Ensembl chr15:65,194,760...65,211,473

G

cold inducible RNA binding protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CIRBP mRNA

NCBI chr19:1,269,332...1,274,880
Ensembl chr19:1,259,384...1,274,880

G

cardiotrophin like cytokine factor 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CLCF1 mRNA

NCBI chr11:67,364,168...67,374,177
Ensembl chr11:67,364,168...67,374,177

G

C-type lectin domain family 2 member A

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CLEC2I mRNA

NCBI chr12:9,877,742...9,932,370
Ensembl chr12:9,898,673...9,932,370

G

C-type lectin domain containing 7A

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CLEC7A mRNA

NCBI chr12:10,116,777...10,130,304
Ensembl chr12:10,116,777...10,130,258

G

clusterin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CLU mRNA

NCBI chr 8:27,596,917...27,614,700
Ensembl chr 8:27,596,917...27,614,700

G

cannabinoid receptor 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CNR2 mRNA

NCBI chr 1:23,870,515...23,913,362
Ensembl chr 1:23,870,515...23,913,362

G

cochlin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of COCH mRNA

NCBI chr14:30,874,559...30,895,615
Ensembl chr14:30,874,514...30,895,065

G

collagen type XI alpha 2 chain

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of COL11A2 mRNA

NCBI chr 6:33,162,694...33,193,519
Ensembl chr 6:33,162,681...33,192,499

G

collagen type VII alpha 1 chain

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of COL7A1 mRNA

NCBI chr 3:48,564,073...48,595,329
Ensembl chr 3:48,564,073...48,595,329

G

collagen like tail subunit of asymmetric acetylcholinesterase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of COLQ mRNA

NCBI chr 3:15,450,133...15,521,706
Ensembl chr 3:15,450,133...15,521,751

G

coronin 1A

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CORO1A mRNA

NCBI chr16:30,183,602...30,189,076
Ensembl chr16:30,182,827...30,189,076

G

coactosin like F-actin binding protein 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of COTL1 mRNA

NCBI chr16:84,565,596...84,618,078
Ensembl chr16:84,565,596...84,618,078

G

cleavage and polyadenylation specific factor 4 like

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of CPSF4L mRNA

NCBI chr17:73,242,101...73,263,778
Ensembl chr17:73,248,449...73,262,352

G

carboxypeptidase X, M14 family member 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CPXM1 mRNA

NCBI chr20:2,794,074...2,800,627
Ensembl chr20:2,794,074...2,800,627

G

complement C3d receptor 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CR2 mRNA

NCBI chr 1:207,454,328...207,489,892
Ensembl chr 1:207,453,024...207,489,895

G

CDP-L-ribitol pyrophosphorylase A

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CRPPA mRNA

NCBI chr 7:16,087,525...16,421,538
Ensembl chr 7:16,087,525...16,502,504

G

cytotoxic and regulatory T cell molecule

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CRTAM mRNA

NCBI chr11:122,838,500...122,872,643
Ensembl chr11:122,838,500...122,872,643

G

cryptochrome circadian regulator 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of CRY1 mRNA

NCBI chr12:106,991,364...107,093,549
Ensembl chr12:106,991,364...107,093,549

G

cysteine and serine rich nuclear protein 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CSRNP2 mRNA

NCBI chr12:51,061,205...51,083,596
Ensembl chr12:51,061,205...51,083,664

G

catenin alpha 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CTNNA3 mRNA

NCBI chr10:65,912,523...67,763,594
Ensembl chr10:65,912,457...67,763,637

G

C-X-C motif chemokine ligand 10

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CXCL10 mRNA

NCBI chr 4:76,021,118...76,023,497
Ensembl chr 4:76,021,118...76,023,497

G

C-X-C motif chemokine ligand 9

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CXCL9 mRNA

NCBI chr 4:76,001,275...76,007,509
Ensembl chr 4:76,001,275...76,007,509

G

cytochrome b-245 beta chain

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CYBB mRNA

NCBI chr X:37,780,059...37,813,461
Ensembl chr X:37,780,018...37,813,461

G

cytochrome P450 family 1 subfamily A member 1

multiple interactions
increases expression

AHR mutant form inhibits the reaction [monomethylarsonic acid results in increased expression of CYP1A1 protein]; monomethylarsonic acid promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of and results in increased activity of CYP1A1 protein]; monomethylarsonic acid promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; monomethylarsonic acid results in increased expression of and results in increased activity of CYP1A1 protein
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of CYP1A1 mRNA
monomethylarsonic acid results in increased expression of CYP1A1 mRNA

PMID:24161444 PMID:34876320

NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536

G

cytochrome P450 family 1 subfamily A member 2

increases expression

monomethylarsonic acid results in increased expression of CYP1A2 mRNA

NCBI chr15:74,748,845...74,756,607
Ensembl chr15:74,748,845...74,756,607

G

cytochrome P450 family 2 subfamily C member 18

increases expression

monomethylarsonic acid results in increased expression of CYP2C11 mRNA

NCBI chr10:94,683,729...94,736,190
Ensembl chr10:94,683,729...94,736,190

G

cytochrome P450 family 4 subfamily F member 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CYP4F18 mRNA

NCBI chr19:15,640,897...15,662,825
Ensembl chr19:15,640,897...15,662,825

G

DAB adaptor protein 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DAB1 mRNA

NCBI chr 1:56,994,778...58,546,726
Ensembl chr 1:56,994,778...58,546,734

G

D-box binding PAR bZIP transcription factor

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DBP mRNA

NCBI chr19:48,630,030...48,637,379
Ensembl chr19:48,630,030...48,637,379

G

doublecortin like kinase 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DCLK3 mRNA

NCBI chr 3:36,712,421...36,764,553
Ensembl chr 3:36,712,421...36,764,553

G

damage specific DNA binding protein 2

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of DDB2 mRNA

NCBI chr11:47,214,454...47,239,217
Ensembl chr11:47,214,465...47,239,217

G

DEF6 guanine nucleotide exchange factor

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DEF6 mRNA

NCBI chr 6:35,297,818...35,321,771
Ensembl chr 6:35,297,818...35,321,771

G

defensin alpha 5

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DEFA21 mRNA

NCBI chr 8:7,055,304...7,056,739
Ensembl chr 8:7,055,304...7,056,739

G

7-dehydrocholesterol reductase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DHCR7 mRNA

NCBI chr11:71,434,411...71,448,393
Ensembl chr11:71,428,193...71,452,868

G

dehydrogenase/reductase 9

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DHRS9 mRNA

NCBI chr 2:169,067,077...169,096,167
Ensembl chr 2:169,064,789...169,096,167

G

DIRAS family GTPase 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DIRAS2 mRNA

NCBI chr 9:90,609,832...90,642,824
Ensembl chr 9:90,609,832...90,642,862

G

dynein axonemal heavy chain 10

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DNAH10 mRNA

NCBI chr12:123,762,301...123,935,720
Ensembl chr12:123,762,188...123,935,720

G

dynein axonemal intermediate chain 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DNAI4 mRNA

NCBI chr 1:66,812,885...66,924,856
Ensembl chr 1:66,812,885...66,924,856

G

DnaJ heat shock protein family (Hsp40) member B13

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DNAJB13 mRNA

NCBI chr11:73,951,026...73,970,281
Ensembl chr11:73,951,026...73,970,366

G

DnaJ heat shock protein family (Hsp40) member B3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DNAJB3 mRNA

NCBI chr 2:233,742,750...233,743,998
Ensembl chr 2:233,743,188...233,743,916
Ensembl chr 2:233,743,188...233,743,916

G

deoxyribonuclease 1 like 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DNASE1L2 mRNA

NCBI chr16:2,236,444...2,238,711
Ensembl chr16:2,235,816...2,238,711

G

deoxyribonuclease 1L3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DNASE1L3 mRNA

NCBI chr 3:58,192,257...58,210,972
Ensembl chr 3:58,192,257...58,214,697

G

DNM3 opposite strand/antisense RNA

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DNM3OS mRNA

NCBI chr 1:172,136,879...172,144,835
Ensembl chr 1:172,138,397...172,144,840

G

DNA methyltransferase 1

decreases expression

monomethylarsonic acid results in decreased expression of DNMT1 mRNA

NCBI chr19:10,133,346...10,194,953
Ensembl chr19:10,133,342...10,231,286

G

dedicator of cytokinesis 10

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DOCK10 mRNA

NCBI chr 2:224,765,090...225,042,468
Ensembl chr 2:224,765,090...225,042,468

G

dedicator of cytokinesis 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DOCK2 mRNA

NCBI chr 5:169,637,275...170,083,382
Ensembl chr 5:169,637,268...170,083,382

G

docking protein 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DOK3 mRNA

NCBI chr 5:177,501,904...177,511,100
Ensembl chr 5:177,501,904...177,511,274

G

dopamine receptor D3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DRD3 mRNA

NCBI chr 3:114,127,580...114,199,407
Ensembl chr 3:114,127,580...114,199,407

G

dual oxidase 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DUOX2 mRNA

NCBI chr15:45,092,650...45,114,172
Ensembl chr15:45,092,650...45,114,172

G

dual oxidase maturation factor 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DUOXA1 mRNA

NCBI chr15:45,117,366...45,129,879
Ensembl chr15:45,117,366...45,129,938

G

dual oxidase maturation factor 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DUOXA2 mRNA

NCBI chr15:45,114,326...45,118,421
Ensembl chr15:45,114,326...45,118,421

G

dual specificity phosphatase 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DUSP1 mRNA

NCBI chr 5:172,768,096...172,771,195
Ensembl chr 5:172,768,096...172,771,195

G

dual specificity phosphatase 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DUSP2 mRNA

NCBI chr 2:96,143,169...96,145,440
Ensembl chr 2:96,143,169...96,145,440

G

dual specificity phosphatase 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DUSP6 mRNA

NCBI chr12:89,347,235...89,352,501
Ensembl chr12:89,347,235...89,352,501

G

ELL associated factor 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of EAF2 mRNA

NCBI chr 3:121,835,209...121,886,526
Ensembl chr 3:121,835,183...121,886,526

G

endothelin 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of EDN1 mRNA

NCBI chr 6:12,230,516...12,297,194
Ensembl chr 6:12,290,361...12,297,194

G

ephrin A3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of EFNA3 mRNA

NCBI chr 1:155,078,837...155,087,538
Ensembl chr 1:155,078,837...155,087,538

G

early growth response 1

increases expression
multiple interactions

monomethylarsonic acid results in increased expression of EGR1 mRNA
[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of EGR1 mRNA

PMID:15345372 PMID:23192986

NCBI chr 5:138,465,479...138,469,303
Ensembl chr 5:138,465,479...138,469,303

G

early growth response 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of EGR3 mRNA

NCBI chr 8:22,687,659...22,693,480
Ensembl chr 8:22,687,659...22,693,480

G

extracellular leucine rich repeat and fibronectin type III domain containing 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ELFN2 mRNA

NCBI chr22:37,340,644...37,427,479
Ensembl chr22:37,367,960...37,427,479
Ensembl chr22:37,367,960...37,427,479

G

endonuclease, poly(U) specific

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ENDOU mRNA

NCBI chr12:47,709,734...47,725,490
Ensembl chr12:47,709,734...47,725,567

G

eomesodermin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of EOMES mRNA

NCBI chr 3:27,715,953...27,722,713
Ensembl chr 3:27,715,949...27,722,711

G

EPM2A glucan phosphatase, laforin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of EPM2A mRNA

NCBI chr 6:145,383,353...145,736,023
Ensembl chr 6:145,382,535...145,736,023

G

epiregulin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of EREG mRNA

NCBI chr 4:74,365,145...74,388,749
Ensembl chr 4:74,365,145...74,388,749

G

estrogen receptor 1

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of ESR1 mRNA

NCBI chr 6:151,656,672...152,129,619
Ensembl chr 6:151,656,691...152,129,619

G

ethanolamine kinase 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ETNK2 mRNA

NCBI chr 1:204,131,062...204,152,044
Ensembl chr 1:204,131,062...204,152,044

G

ETS proto-oncogene 1, transcription factor

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ETS1 mRNA

NCBI chr11:128,458,765...128,587,558
Ensembl chr11:128,458,761...128,587,558

G

exophilin 5

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of EXPH5 mRNA

NCBI chr11:108,505,435...108,607,536
Ensembl chr11:108,505,435...108,593,768

G

fatty acid binding protein 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FABP1 mRNA

NCBI chr 2:88,122,982...88,128,062
Ensembl chr 2:88,122,982...88,128,062

G

fatty acid binding protein 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FABP3 mRNA

NCBI chr 1:31,359,588...31,373,076
Ensembl chr 1:31,365,253...31,376,850

G

family with sequence similarity 151 member A

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of FAM151A mRNA

NCBI chr 1:54,609,181...54,623,525
Ensembl chr 1:54,609,181...54,623,556

G

FAM161 centrosomal protein B

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of FAM161B mRNA

NCBI chr14:73,922,699...73,950,094
Ensembl chr14:73,931,501...73,950,414

G

family with sequence similarity 169 member B, pseudogene

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FAM169B mRNA

NCBI chr15:98,437,162...98,514,336
Ensembl chr15:98,441,071...98,520,386
Ensembl chr15:98,441,071...98,520,386

G

family with sequence similarity 89 member A

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FAM89A mRNA

NCBI chr 1:231,018,958...231,040,254
Ensembl chr 1:231,018,958...231,040,254

G

FA complementation group D2

multiple interactions

[monomethylarsonic acid results in decreased activity of FANCD2 protein] which results in increased susceptibility to diepoxybutane; [monomethylarsonic acid results in decreased activity of FANCD2 protein] which results in increased susceptibility to Hydroxyurea; [monomethylarsonic acid results in decreased activity of FANCD2 protein] which results in increased susceptibility to Mitomycin

NCBI chr 3:10,026,437...10,101,932
Ensembl chr 3:10,026,370...10,101,932

G

Fas cell surface death receptor

decreases expression

monomethylarsonic acid results in decreased expression of FAS mRNA

NCBI chr10:88,964,050...89,017,059
Ensembl chr10:88,953,813...89,029,605

G

Fas ligand

increases expression

monomethylarsonic acid results in increased expression of FASLG mRNA

NCBI chr 1:172,659,103...172,666,876
Ensembl chr 1:172,659,103...172,666,876

G

fructose-bisphosphatase 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FBP1 mRNA

NCBI chr 9:94,603,133...94,640,263
Ensembl chr 9:94,603,133...94,640,249

G

F-box and leucine rich repeat protein 22

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of FBXL22 mRNA

NCBI chr15:63,597,387...63,608,516
Ensembl chr15:63,597,353...63,602,428

G

F-box protein 24

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of FBXO24 mRNA

NCBI chr 7:100,586,328...100,601,117
Ensembl chr 7:100,583,982...100,601,117

G

Fc epsilon receptor II

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FCER2A mRNA

NCBI chr19:7,688,776...7,702,131
Ensembl chr19:7,688,758...7,702,146

G

Fc receptor like 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FCRL1 mRNA

NCBI chr 1:157,794,403...157,820,120
Ensembl chr 1:157,794,403...157,820,120

G

Fc receptor like A

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FCRLA mRNA

NCBI chr 1:161,707,229...161,714,352
Ensembl chr 1:161,706,972...161,714,352

G

farnesyl-diphosphate farnesyltransferase 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FDFT1 mRNA

NCBI chr 8:11,795,582...11,839,309
Ensembl chr 8:11,795,573...11,839,395

G

farnesyl diphosphate synthase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FDPS mRNA

NCBI chr 1:155,308,866...155,320,665
Ensembl chr 1:155,308,748...155,320,666

G

fer-1 like family member 5

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of FER1L5 mRNA

NCBI chr 2:96,642,764...96,704,883
Ensembl chr 2:96,642,737...96,704,887

G

free fatty acid receptor 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FFAR1 mRNA

NCBI chr19:35,347,902...35,353,864
Ensembl chr19:35,347,902...35,353,864

G

fibroblast growth factor 11

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of FGF11 mRNA

NCBI chr17:7,438,298...7,444,937
Ensembl chr17:7,438,273...7,444,937

G

fibroblast growth factor 2

increases expression

monomethylarsonic acid results in increased expression of FGF2 mRNA

NCBI chr 4:122,826,682...122,898,236
Ensembl chr 4:122,826,682...122,898,236

G

fibroblast growth factor binding protein 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FGFBP3 mRNA

NCBI chr10:91,906,584...91,909,486
Ensembl chr10:91,906,584...91,909,486

G

FGR proto-oncogene, Src family tyrosine kinase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FGR mRNA

NCBI chr 1:27,612,064...27,635,185
Ensembl chr 1:27,612,064...27,635,185

G

FKBP prolyl isomerase 5

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of FKBP5 mRNA

NCBI chr 6:35,573,590...35,728,583
Ensembl chr 6:35,573,585...35,728,583

G

flagellum associated containing coiled-coil domains 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FLACC1 mRNA

NCBI chr 2:201,288,271...201,364,289
Ensembl chr 2:201,288,271...201,357,398

G

Fli-1 proto-oncogene, ETS transcription factor

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FLI1 mRNA

NCBI chr11:128,685,351...128,813,267
Ensembl chr11:128,686,535...128,813,267

G

filamin C

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FLNC mRNA

NCBI chr 7:128,830,406...128,859,272
Ensembl chr 7:128,830,406...128,859,274

G

fms related receptor tyrosine kinase 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FLT3 mRNA

NCBI chr13:28,003,274...28,100,576
Ensembl chr13:28,003,274...28,100,592

G

fibronectin type III domain containing 10

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FNDC10 mRNA

NCBI chr 1:1,598,012...1,600,135
Ensembl chr 1:1,598,012...1,600,135

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of FOS mRNA
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of FOS mRNA

PMID:23192986 PMID:34876320

NCBI chr14:75,278,828...75,282,230
Ensembl chr14:75,278,826...75,282,230

G

formyl peptide receptor 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of FPR1 mRNA

NCBI chr19:51,745,172...51,751,878
Ensembl chr19:51,745,172...51,804,115

G

fascin actin-bundling protein 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FSCN1 mRNA

NCBI chr 7:5,592,816...5,606,655
Ensembl chr 7:5,592,816...5,606,655

G

fucosyltransferase 1 (H blood group)

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of FUT1 mRNA

NCBI chr19:48,748,011...48,755,358
Ensembl chr19:48,748,011...48,755,390

G

growth arrest and DNA damage inducible alpha

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of GADD45A mRNA

NCBI chr 1:67,685,201...67,688,334
Ensembl chr 1:67,685,201...67,688,334

G

guanylate binding protein 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GBP4 mRNA

NCBI chr 1:89,181,144...89,198,942
Ensembl chr 1:89,181,144...89,198,942

G

guanylate binding protein family member 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GBP9 mRNA

NCBI chr 1:89,364,059...89,388,160
Ensembl chr 1:89,364,059...89,388,160

G

GTP cyclohydrolase 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of GCH1 mRNA

NCBI chr14:54,842,017...54,902,826
Ensembl chr14:54,842,008...54,902,826

G

germinal center associated signaling and motility

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GCSAM mRNA

NCBI chr 3:112,120,839...112,133,248
Ensembl chr 3:112,120,839...112,133,270

G

growth differentiation factor 15

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GDF15 mRNA

NCBI chr19:18,386,158...18,389,176
Ensembl chr19:18,374,731...18,389,176

G

GTPase, IMAP family member 5

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GIMAP5 mRNA

NCBI chr 7:150,737,418...150,743,646
Ensembl chr 7:150,722,253...150,750,033

G

GTPase, IMAP family member 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GIMAP6 mRNA

NCBI chr 7:150,625,375...150,632,385
Ensembl chr 7:150,625,375...150,632,648

G

GTPase, IMAP family member 8

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GIMAP8 mRNA

NCBI chr 7:150,450,630...150,479,393
Ensembl chr 7:150,450,630...150,479,393

G

gap junction protein beta 1

increases expression

monomethylarsonic acid results in increased expression of GJB1 mRNA

NCBI chr X:71,215,239...71,225,516
Ensembl chr X:71,212,811...71,225,516

G

GLI family zinc finger 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GLI1 mRNA

NCBI chr12:57,459,785...57,472,268
Ensembl chr12:57,459,785...57,472,268

G

glycine receptor beta

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of GLRB mRNA

NCBI chr 4:157,076,150...157,172,090
Ensembl chr 4:157,076,125...157,172,090

G

G protein subunit alpha 15

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GNA15 mRNA

NCBI chr19:3,136,033...3,163,749
Ensembl chr19:3,136,033...3,163,749

G

G protein subunit alpha transducin 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GNAT1 mRNA

NCBI chr 3:50,191,610...50,197,696
Ensembl chr 3:50,191,610...50,197,696

G

G protein-coupled receptor 132

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GPR132 mRNA

NCBI chr14:105,049,395...105,065,430
Ensembl chr14:105,049,395...105,065,445

G

G protein-coupled receptor 157

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GPR157 mRNA

NCBI chr 1:9,100,305...9,129,102
Ensembl chr 1:9,100,305...9,129,102

G

G protein-coupled receptor 17

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of GPR17 mRNA

NCBI chr 2:127,646,153...127,652,639
Ensembl chr 2:127,645,864...127,652,639

G

G protein-coupled receptor 174

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GPR174 mRNA

NCBI chr X:79,144,688...79,175,318
Ensembl chr X:79,144,688...79,175,318

G

G protein-coupled receptor 179

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GPR179 mRNA

NCBI chr17:38,324,571...38,343,956
Ensembl chr17:38,324,571...38,343,956

G

G protein-coupled receptor 18

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GPR18 mRNA

NCBI chr13:99,254,739...99,258,379
Ensembl chr13:99,254,732...99,261,744

G

G protein-coupled receptor 183

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GPR183 mRNA

NCBI chr13:99,294,539...99,307,399
Ensembl chr13:99,294,539...99,307,399

G

G protein-coupled receptor 34

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GPR34 mRNA

NCBI chr X:41,688,973...41,697,275
Ensembl chr X:41,688,973...41,697,275

G

glutathione peroxidase 7

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of GPX7 mRNA

NCBI chr 1:52,602,371...52,609,051
Ensembl chr 1:52,602,371...52,609,051

G

GRAM domain containing 2A

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GRAMD2A mRNA

NCBI chr15:72,159,806...72,197,787
Ensembl chr15:72,159,806...72,197,787

G

GRB2 related adaptor protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GRAP mRNA

NCBI chr17:19,020,656...19,051,373
Ensembl chr17:19,020,656...19,047,011

G

glutathione S-transferase alpha 2

increases expression
decreases expression

monomethylarsonic acid results in increased expression of GSTA2 mRNA
monomethylarsonic acid results in decreased expression of GSTA2 mRNA; monomethylarsonic acid results in decreased expression of GSTA2 protein

PMID:16436460 PMID:17481689

NCBI chr 6:52,750,087...52,763,475
Ensembl chr 6:52,750,087...52,763,475

G

glutathione S-transferase mu 1

increases expression

monomethylarsonic acid results in increased expression of GSTM1 mRNA; monomethylarsonic acid results in increased expression of GSTM1 protein

NCBI chr 1:109,687,817...109,693,745
Ensembl chr 1:109,687,814...109,709,039

G

glutathione S-transferase omega 1

increases reduction
multiple interactions

GSTO1 protein results in increased reduction of monomethylarsonic acid
[GSTO1 protein results in increased metabolism of monomethylarsonic acid] which results in increased chemical synthesis of monomethylarsonous acid

PMID:12928150 PMID:15929903

NCBI chr10:104,254,173...104,267,455
Ensembl chr10:104,235,356...104,267,459

G

glutathione S-transferase pi 1

increases expression

monomethylarsonic acid results in increased expression of GSTP1 mRNA

NCBI chr11:67,583,812...67,586,653
Ensembl chr11:67,583,742...67,586,656

G

glutathione S-transferase theta 1

affects methylation
multiple interactions

GSTT1 protein affects the methylation of monomethylarsonic acid
[GSTT1 gene polymorphism affects the metabolism of Arsenic] which affects the abundance of monomethylarsonic acid

PMID:17431481 PMID:32650499

G

guanylate cyclase activator 1B

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of GUCA1B mRNA

NCBI chr 6:42,183,284...42,194,956
Ensembl chr 6:42,183,284...42,194,956

G

granzyme A

decreases expression

monomethylarsonic acid results in decreased expression of GZMA mRNA

NCBI chr 5:55,102,646...55,110,252
Ensembl chr 5:55,102,646...55,110,252

G

granzyme K

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GZMK mRNA

NCBI chr 5:55,024,256...55,034,570
Ensembl chr 5:55,024,256...55,034,570

G

H4 clustered histone 14

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of H4C14 mRNA

NCBI chr 1:149,832,657...149,833,052
Ensembl chr 1:149,832,657...149,839,767

G

3-hydroxyanthranilate 3,4-dioxygenase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HAAO mRNA

NCBI chr 2:42,767,089...42,792,583
Ensembl chr 2:42,767,089...42,792,593

G

hematopoietic cell-specific Lyn substrate 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HCLS1 mRNA

NCBI chr 3:121,631,399...121,660,903
Ensembl chr 3:121,631,399...121,660,927

G

hyperpolarization activated cyclic nucleotide gated potassium and sodium channel 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HCN2 mRNA

NCBI chr19:589,881...617,159
Ensembl chr19:589,881...617,159

G

histidine decarboxylase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HDC mRNA

NCBI chr15:50,241,947...50,265,726
Ensembl chr15:50,241,947...50,265,965

G

hedgehog acyltransferase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HHAT mRNA

NCBI chr 1:210,327,328...210,676,290
Ensembl chr 1:210,328,252...210,676,296

G

hematopoietically expressed homeobox

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HHEX mRNA

NCBI chr10:92,689,955...92,695,647
Ensembl chr10:92,689,955...92,695,647

G

hexokinase 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of HK2 mRNA

NCBI chr 2:74,834,127...74,893,359
Ensembl chr 2:74,834,127...74,893,359

G

major histocompatibility complex, class I, B

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of H2-M2 mRNA

NCBI chr 6:31,353,875...31,357,179
Ensembl chr 6:31,353,872...31,367,067

G

major histocompatibility complex, class II, DO alpha

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of H2-OA mRNA

NCBI chr 6:33,004,182...33,009,591
Ensembl chr 6:33,004,182...33,009,591

G

major histocompatibility complex, class II, DO beta

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of H2-OB mRNA

NCBI chr 6:32,812,763...32,817,002
Ensembl chr 6:32,812,763...32,820,466

G

3-hydroxy-3-methylglutaryl-CoA synthase 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HMGCS1 mRNA

NCBI chr 5:43,287,470...43,313,412
Ensembl chr 5:43,287,470...43,313,512

G

3-hydroxy-3-methylglutaryl-CoA synthase 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HMGCS2 mRNA

NCBI chr 1:119,747,996...119,768,932
Ensembl chr 1:119,748,002...119,768,905

G

heme oxygenase 1

increases expression
multiple interactions
decreases expression

monomethylarsonic acid results in increased expression of HMOX1 mRNA
[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of HMOX1 mRNA
monomethylarsonic acid results in decreased expression of HMOX1 mRNA

PMID:15345372 PMID:23192986 PMID:24091636

NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214

G

4-hydroxy-2-oxoglutarate aldolase 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HOGA1 mRNA

NCBI chr10:97,584,389...97,612,802
Ensembl chr10:97,584,323...97,612,802

G

hippocalcin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of HPCA mRNA

NCBI chr 1:32,885,996...32,894,646
Ensembl chr 1:32,885,994...32,898,441

G

heparan sulfate-glucosamine 3-sulfotransferase 3B1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of HS3ST3B1 mRNA

NCBI chr17:14,301,081...14,349,404
Ensembl chr17:14,301,081...14,349,404

G

heat shock transcription factor 2 binding protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HSF2BP mRNA

NCBI chr21:43,444,972...43,659,488
Ensembl chr21:43,529,186...43,659,488

G

heat shock protein family A (Hsp70) member 1A

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of HSPA1A mRNA

NCBI chr 6:31,815,543...31,817,942
Ensembl chr 6:31,815,543...31,817,946

G

heat shock protein family A (Hsp70) member 1B

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of HSPA1B mRNA

NCBI chr 6:31,827,738...31,830,254
Ensembl chr 6:31,827,738...31,830,254

G

heat shock protein family A (Hsp70) member 8

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of HSPA8 mRNA

NCBI chr11:123,057,489...123,062,462
Ensembl chr11:123,057,489...123,063,230

G

heat shock protein family B (small) member 7

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HSPB7 mRNA

NCBI chr 1:16,014,029...16,019,594
Ensembl chr 1:16,014,028...16,019,594

G

heat shock protein family H (Hsp110) member 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of HSPH1 mRNA

NCBI chr13:31,134,973...31,162,388
Ensembl chr13:31,134,973...31,162,388

G

hydrogen voltage gated channel 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HVCN1 mRNA

NCBI chr12:110,648,686...110,704,952
Ensembl chr12:110,627,841...110,704,950

G

intercellular adhesion molecule 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ICAM1 mRNA

NCBI chr19:10,271,120...10,286,615
Ensembl chr19:10,271,093...10,286,615

G

inducible T cell costimulator

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ICOS mRNA

NCBI chr 2:203,936,763...203,961,577
Ensembl chr 2:203,936,763...203,961,577

G

insulin like growth factor 1 receptor

increases expression

monomethylarsonic acid results in increased expression of IGF1R mRNA

NCBI chr15:98,648,539...98,964,530
Ensembl chr15:98,648,539...98,964,530

G

insulin like growth factor binding protein 1

increases expression

monomethylarsonic acid results in increased expression of IGFBP1 mRNA

NCBI chr 7:45,888,488...45,893,660
Ensembl chr 7:45,888,360...45,893,660

G

immunoglobulin heavy constant alpha 2 (A2m marker)

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGHA mRNA

NCBI chr14:105,586,937...105,588,394
Ensembl chr14:105,583,731...105,588,395

G

immunoglobulin heavy constant delta

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGHD mRNA

NCBI chr14:105,838,401...105,845,677
Ensembl chr14:105,836,765...105,845,677

G

immunoglobulin heavy constant mu

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGHM mRNA

NCBI chr14:105,851,966...105,856,217
Ensembl chr14:105,851,705...105,856,218

G

immunoglobulin heavy variable 1-18

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGHV1-18 mRNA

NCBI chr14:106,184,899...106,185,335
Ensembl chr14:106,184,901...106,185,394

G

immunoglobulin heavy variable 3-20

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGHV10-1 mRNA

NCBI chr14:106,210,936...106,211,391
Ensembl chr14:106,210,936...106,211,453

G

immunoglobulin heavy variable 3-23

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGHV5-9 mRNA

NCBI chr14:106,268,606...106,269,061
Ensembl chr14:106,268,606...106,269,140

G

immunoglobulin heavy variable 3-33

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGHV5-17 mRNA

NCBI chr14:106,359,791...106,360,244
Ensembl chr14:106,359,793...106,360,324

G

immunoglobulin heavy variable 3/OR16-13 (non-functional)

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of IGHV4-1 mRNA

NCBI chr16:33,827,366...33,827,659
Ensembl chr16:33,827,214...33,827,661

G

immunoglobulin heavy variable 4/OR15-8 (non-functional)

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of IGHV3-5 mRNA

Ensembl chr15:22,184,967...22,185,402

G

immunoglobulin kappa variable 2D-29

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGKV2-109 mRNA

NCBI chr 2:89,947,542...89,948,271
Ensembl chr 2:89,947,512...89,948,269

G

immunoglobulin kappa variable 2D-30

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGKV1-133 mRNA

NCBI chr 2:89,936,894...89,937,679
Ensembl chr 2:89,936,859...89,937,679

G

immunoglobulin lambda constant 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGLC2 mRNA

NCBI chr22:22,900,976...22,901,295
Ensembl chr22:22,900,976...22,901,437

G

IKAROS family zinc finger 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IKZF1 mRNA

NCBI chr 7:50,303,455...50,405,101
Ensembl chr 7:50,304,068...50,405,101

G

interleukin 10 receptor subunit alpha

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IL10RA mRNA

NCBI chr11:117,986,394...118,003,037
Ensembl chr11:117,986,370...118,003,037

G

interleukin 13 receptor subunit alpha 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IL13RA2 mRNA

NCBI chr X:115,003,982...115,017,616
Ensembl chr X:115,003,975...115,019,977

G

interleukin 20 receptor subunit beta

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IL20RB mRNA

NCBI chr 3:136,957,983...137,011,085
Ensembl chr 3:136,946,230...137,011,085

G

interleukin 21 receptor

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IL21R mRNA

NCBI chr16:27,402,174...27,452,042
Ensembl chr16:27,402,174...27,452,042

G

interleukin 22 receptor subunit alpha 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IL22RA2 mRNA

NCBI chr 6:137,143,820...137,173,644
Ensembl chr 6:137,143,820...137,173,648

G

interleukin 27 receptor subunit alpha

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IL27RA mRNA

NCBI chr19:14,031,762...14,053,218
Ensembl chr19:14,031,762...14,053,218

G

interleukin 36 beta

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IL36B mRNA

NCBI chr 2:113,022,089...113,052,867
Ensembl chr 2:113,022,089...113,052,867

G

interleukin 5 receptor subunit alpha

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IL5RA mRNA

NCBI chr 3:3,066,324...3,110,374
Ensembl chr 3:3,066,324...3,126,613

G

interleukin 7 receptor

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IL7R mRNA

NCBI chr 5:35,856,891...35,879,603
Ensembl chr 5:35,852,695...35,879,603

G

interleukin 9 receptor

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IL9R mRNA

NCBI chr  X:155,997,696...156,013,020
NCBI chr  Y:57,184,072...57,197,869
Ensembl chr  Y:57,184,216...57,197,337
Ensembl chr  X:57,184,216...57,197,337

G

INS-IGF2 readthrough

multiple interactions

monomethylarsonic acid inhibits the reaction [INS1 protein results in increased uptake of Glucose]

NCBI chr11:2,129,117...2,161,209
Ensembl chr11:2,132,538...2,161,209

G

insulin induced gene 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of INSIG1 mRNA

NCBI chr 7:155,297,878...155,310,235
Ensembl chr 7:155,297,776...155,310,235

G

interferon regulatory factor 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IRF4 mRNA

NCBI chr 6:391,752...411,443
Ensembl chr 6:391,739...411,443

G

integrin subunit alpha 10

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ITGA10 mRNA

NCBI chr 1:145,891,208...145,910,050
Ensembl chr 1:145,891,208...145,910,111

G

integrin subunit alpha 8

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ITGA8 mRNA

NCBI chr10:15,513,954...15,719,922
Ensembl chr10:15,513,954...15,719,922

G

integrin subunit alpha L

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ITGAL mRNA

NCBI chr16:30,472,742...30,523,185
Ensembl chr16:30,472,658...30,523,567

G

integrin subunit beta 8

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ITGB8 mRNA

NCBI chr 7:20,329,766...20,415,754
Ensembl chr 7:20,330,702...20,415,754

G

inter-alpha-trypsin inhibitor heavy chain 3

increases expression

monomethylarsonic acid results in increased expression of ITIH3 mRNA

NCBI chr 3:52,794,796...52,808,797
Ensembl chr 3:52,794,768...52,808,799

G

ITPRIP like 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ITPRIPL2 mRNA

NCBI chr16:19,113,964...19,121,629
Ensembl chr16:19,113,932...19,121,629

G

IZUMO1 receptor, JUNO

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IZUMO1R mRNA

NCBI chr11:94,304,580...94,308,146
Ensembl chr11:94,304,580...94,308,146

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of JUN mRNA

NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,776,845...58,784,048

G

potassium voltage-gated channel modifier subfamily G member 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of KCNG1 mRNA

NCBI chr20:51,003,656...51,023,107
Ensembl chr20:51,003,656...51,023,107

G

potassium voltage-gated channel interacting protein 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of KCNIP4 mRNA

NCBI chr 4:20,728,606...21,948,772
Ensembl chr 4:20,728,606...21,948,772

G

potassium inwardly rectifying channel subfamily J member 13

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of KCNJ13 mRNA

NCBI chr 2:232,765,802...232,776,565
Ensembl chr 2:232,765,802...232,776,565

G

potassium two pore domain channel subfamily K member 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of KCNK6 mRNA

NCBI chr19:38,319,845...38,332,076
Ensembl chr19:38,319,845...38,332,076

G

kelch like family member 30

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of KLHL30 mRNA

NCBI chr 2:238,138,668...238,152,947
Ensembl chr 2:238,138,668...238,152,947

G

kelch like family member 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of KLHL6 mRNA

NCBI chr 3:183,487,551...183,555,706
Ensembl chr 3:183,487,551...183,555,706

G

killer cell lectin like receptor B1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of KLRB1 mRNA

NCBI chr12:9,594,551...9,607,916
Ensembl chr12:9,594,551...9,607,916

G

kynurenine 3-monooxygenase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of KMO mRNA

NCBI chr 1:241,532,378...241,595,642
Ensembl chr 1:241,532,134...241,595,642

G

keratin 12

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of KRT12 mRNA

NCBI chr17:40,861,303...40,867,223
Ensembl chr17:40,861,303...40,867,223

G

keratin 17

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of KRT17 mRNA

NCBI chr17:41,619,442...41,624,575
Ensembl chr17:41,619,442...41,624,842

G

keratin 18

decreases expression

monomethylarsonic acid results in decreased expression of KRT18 mRNA

NCBI chr12:52,948,855...52,952,906
Ensembl chr12:52,948,871...52,952,906

G

keratin 27

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of KRT27 mRNA

NCBI chr17:40,776,808...40,782,550
Ensembl chr17:40,776,808...40,782,550

G

L3MBTL histone methyl-lysine binding protein 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of L3MBTL3 mRNA

NCBI chr 6:130,018,581...130,141,438
Ensembl chr 6:130,013,699...130,141,449

G

ladinin 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LAD1 mRNA

NCBI chr 1:201,380,833...201,399,324
Ensembl chr 1:201,380,833...201,399,915

G

leucyl-tRNA synthetase 2, mitochondrial

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LARS2 mRNA

NCBI chr 3:45,388,576...45,549,407
Ensembl chr 3:45,388,561...45,554,726

G

lymphocyte transmembrane adaptor 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LAX1 mRNA

NCBI chr 1:203,765,183...203,776,372
Ensembl chr 1:203,765,177...203,776,372

G

lymphocyte cytosolic protein 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LCP1 mRNA

NCBI chr13:46,125,923...46,182,177
Ensembl chr13:46,125,920...46,211,871

G

low density lipoprotein receptor

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LDLR mRNA

NCBI chr19:11,089,463...11,133,820
Ensembl chr19:11,089,418...11,133,820

G

lymphoid enhancer binding factor 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LEF1 mRNA

NCBI chr 4:108,047,548...108,168,932
Ensembl chr 4:108,047,545...108,168,956

G

galectin 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LGALS2 mRNA

NCBI chr22:37,570,248...37,580,087
Ensembl chr22:37,570,248...37,582,616

G

galectin 8

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of LGALS8 mRNA

NCBI chr 1:236,518,214...236,552,981
Ensembl chr 1:236,518,000...236,552,981

G

LHFPL tetraspan subfamily member 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of LHFPL2 mRNA

NCBI chr 5:78,485,230...78,648,772
Ensembl chr 5:78,485,215...78,770,021

G

lipase C, hepatic type

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LIPC mRNA

NCBI chr15:58,431,991...58,569,844
Ensembl chr15:58,410,569...58,569,844

G

lysophosphatidylcholine acyltransferase 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of LPCAT4 mRNA

NCBI chr15:34,358,633...34,367,196
Ensembl chr15:34,358,633...34,367,196

G

leupaxin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LPXN mRNA

NCBI chr11:58,526,871...58,578,891
Ensembl chr11:58,526,871...58,578,220

G

leucine rich repeat containing 31

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LRRC31 mRNA

NCBI chr 3:169,839,172...169,869,935
Ensembl chr 3:169,839,172...169,869,935

G

leucine rich repeat kinase 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LRRK2 mRNA

NCBI chr12:40,224,997...40,369,285
Ensembl chr12:40,196,744...40,369,285

G

lanosterol synthase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LSS mRNA

NCBI chr21:46,188,446...46,228,774
Ensembl chr21:46,188,141...46,228,824

G

lymphotoxin alpha

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LTA mRNA

NCBI chr 6:31,560,610...31,574,324
Ensembl chr 6:31,572,054...31,574,324

G

lymphotoxin beta

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LTB mRNA

NCBI chr 6:31,580,558...31,582,425
Ensembl chr 6:31,580,525...31,582,522

G

leukotriene B4 receptor 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LTB4R2 mRNA

NCBI chr14:24,310,140...24,312,038
Ensembl chr14:24,305,734...24,312,053

G

lymphocyte antigen 6 family member D

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LY6D mRNA

NCBI chr 8:142,784,882...142,786,539
Ensembl chr 8:142,784,882...142,786,539

G

lymphocyte antigen 6 family member G6C

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of LY6G6C mRNA

NCBI chr 6:31,718,648...31,721,746
Ensembl chr 6:31,718,648...31,721,746

G

lymphocyte antigen 9

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LY9 mRNA

NCBI chr 1:160,796,174...160,828,255
Ensembl chr 1:160,796,074...160,828,261

G

LYL1 basic helix-loop-helix family member

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LYL1 mRNA

NCBI chr19:13,099,033...13,102,858
Ensembl chr19:13,099,033...13,103,161

G

mitogen-activated protein kinase kinase kinase 19

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MAP3K19 mRNA

NCBI chr 2:134,964,491...135,047,447
Ensembl chr 2:134,964,485...135,047,468

G

mitogen-activated protein kinase kinase kinase 9

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MAP3K9 mRNA

NCBI chr14:70,722,526...70,809,513
Ensembl chr14:70,722,526...70,809,534

G

mitogen-activated protein kinase kinase kinase kinase 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MAP4K1 mRNA

NCBI chr19:38,587,641...38,617,953
Ensembl chr19:38,587,641...38,618,882

G

mitogen-activated protein kinase 1

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of MAPK1 mRNA

NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680

G

mitogen-activated protein kinase 15

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MAPK15 mRNA

NCBI chr 8:143,716,349...143,722,458
Ensembl chr 8:143,716,340...143,722,458

G

melanin concentrating hormone receptor 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MCHR1 mRNA

NCBI chr22:40,679,484...40,682,812
Ensembl chr22:40,679,273...40,682,812

G

MDM2 proto-oncogene

increases expression
multiple interactions

monomethylarsonic acid results in increased expression of MDM2 mRNA
[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of MDM2 mRNA

PMID:17481689 PMID:23192986

NCBI chr12:68,808,172...68,850,686
Ensembl chr12:68,808,177...68,845,544

G

myocyte enhancer factor 2C

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MEF2C mRNA

NCBI chr 5:88,717,117...88,904,105
Ensembl chr 5:88,717,117...88,904,257

G

meiosis specific with coiled-coil domain

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MEIOC mRNA

NCBI chr17:44,656,468...44,677,087
Ensembl chr17:44,656,404...44,690,308

G

milk fat globule EGF and factor V/VIII domain containing

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MFGE8 mRNA

NCBI chr15:88,898,683...88,913,379
Ensembl chr15:88,898,683...88,913,468

G

major facilitator superfamily domain containing 12

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MFSD12 mRNA

NCBI chr19:3,538,275...3,557,586
Ensembl chr19:3,538,261...3,574,290

G

MFSD2 lysolipid transporter B, sphingolipid

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MFSD2B mRNA

NCBI chr 2:24,010,085...24,026,775
Ensembl chr 2:24,010,081...24,063,321

G

microRNA 145

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MIR145A mRNA

NCBI chr 5:149,430,646...149,430,733
Ensembl chr 5:149,430,646...149,430,733

G

MIR155 host gene

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MIR155HG mRNA

NCBI chr21:25,562,145...25,575,168
Ensembl chr21:25,561,810...25,575,168

G

microRNA 192

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MIR192 mRNA

NCBI chr11:64,891,137...64,891,246
Ensembl chr11:64,891,137...64,891,246

G

mohawk homeobox

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MKX mRNA

NCBI chr10:27,672,874...27,745,819
Ensembl chr10:27,672,874...27,746,060

G

maestro heat like repeat family member 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MROH6 mRNA

NCBI chr 8:143,566,192...143,572,772
Ensembl chr 8:143,566,192...143,572,772

G

maestro heat like repeat family member 7

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MROH7 mRNA

NCBI chr 1:54,641,786...54,710,266
Ensembl chr 1:54,641,754...54,710,266

G

membrane spanning 4-domains A1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MS4A1 mRNA

NCBI chr11:60,455,847...60,470,752
Ensembl chr11:60,455,846...60,470,752

G

membrane spanning 4-domains A18

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MS4A18 mRNA

NCBI chr11:60,724,720...60,745,028
Ensembl chr11:60,724,720...60,745,028

G

mutS homolog 2

decreases expression

monomethylarsonic acid results in decreased expression of MSH2 mRNA

NCBI chr 2:47,403,067...47,709,830
Ensembl chr 2:47,403,067...47,663,146

G

misato mitochondrial distribution and morphology regulator 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MSTO1 mRNA

NCBI chr 1:155,563,246...155,614,967
Ensembl chr 1:155,563,235...155,614,951

G

mitochondrially encoded 12S rRNA

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MT-RNR1 mRNA

NCBI chr MT:648...1,601
Ensembl chr MT:648...1,601

G

mitochondrially encoded 16S rRNA

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MT-RNR2 mRNA

NCBI chr MT:1,671...3,229
Ensembl chr MT:1,671...3,229

G

metallothionein 1E

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of MT1E mRNA

NCBI chr16:56,625,781...56,627,112
Ensembl chr16:56,625,475...56,627,112

G

metallothionein 1X

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MT1 mRNA

NCBI chr16:56,682,470...56,684,196
Ensembl chr16:56,682,470...56,684,196

G

metallothionein 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MT4 mRNA

NCBI chr16:56,565,073...56,568,957
Ensembl chr16:56,565,073...56,568,957

G

mevalonate diphosphate decarboxylase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MVD mRNA

NCBI chr16:88,651,940...88,663,091
Ensembl chr16:88,651,935...88,663,161

G

mevalonate kinase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MVK mRNA

NCBI chr12:109,573,272...109,598,125
Ensembl chr12:109,573,255...109,598,125

G

MX dynamin like GTPase 1

multiple interactions

[Arsenic results in increased abundance of monomethylarsonic acid] which affects the expression of MX1 mRNA
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MX1 mRNA

PMID:28793237 PMID:34876320

NCBI chr21:41,420,558...41,459,214
Ensembl chr21:41,420,020...41,470,071

G

MAX dimerization protein 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MXD3 mRNA

NCBI chr 5:177,305,499...177,312,752
Ensembl chr 5:177,301,461...177,312,757

G

MYB proto-oncogene like 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MYBL1 mRNA

NCBI chr 8:66,562,175...66,613,218
Ensembl chr 8:66,562,175...66,614,247

G

MYC proto-oncogene, bHLH transcription factor

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of MYC mRNA

NCBI chr 8:127,735,434...127,742,951
Ensembl chr 8:127,735,434...127,742,951

G

myosin IG

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MYO1G mRNA

NCBI chr 7:44,962,662...44,979,015
Ensembl chr 7:44,962,662...44,979,088

G

myotilin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MYOT mRNA

NCBI chr 5:137,867,860...137,887,851
Ensembl chr 5:137,867,858...137,887,851

G

marginal zone B and B1 cell specific protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MZB1 mRNA

NCBI chr 5:139,387,467...139,389,913
Ensembl chr 5:139,387,467...139,390,081

G

N-6 adenine-specific DNA methyltransferase 1

increases abundance

N6AMT1 gene polymorphism results in increased abundance of monomethylarsonic acid

NCBI chr21:28,575,598...28,885,367
Ensembl chr21:28,872,191...28,885,371

G

N-acetylated alpha-linked acidic dipeptidase like 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NAALADL1 mRNA

NCBI chr11:65,044,818...65,061,203
Ensembl chr11:65,044,818...65,058,553

G

napsin A aspartic peptidase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NAPSA mRNA

NCBI chr19:50,358,477...50,365,639
Ensembl chr19:50,358,472...50,365,830

G

neutrophil cytosolic factor 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NCF1 mRNA

NCBI chr 7:74,774,011...74,789,315
Ensembl chr 7:74,774,011...74,789,315

G

non-compact myelin associated protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NCMAP mRNA

NCBI chr 1:24,556,087...24,609,328
Ensembl chr 1:24,556,087...24,609,328

G

N-myc downstream regulated 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NDRG1 mRNA

NCBI chr 8:133,237,175...133,297,252
Ensembl chr 8:133,237,175...133,302,022

G

N-deacetylase and N-sulfotransferase 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NDST3 mRNA

NCBI chr 4:118,033,322...118,258,634
Ensembl chr 4:118,033,618...118,258,634

G

nuclear paraspeckle assembly transcript 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of NEAT1 mRNA

NCBI chr11:65,422,798...65,445,540
Ensembl chr11:65,422,774...65,445,540

G

nebulin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NEB mRNA

NCBI chr 2:151,485,339...151,734,476
Ensembl chr 2:151,485,336...151,734,487

G

nectin cell adhesion molecule 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NECTIN1 mRNA

NCBI chr11:119,638,098...119,729,200
Ensembl chr11:119,623,408...119,729,200

G

NFE2 like bZIP transcription factor 1

multiple interactions

[NFE2L1 protein alternative form results in decreased methylation of arsenite] which results in decreased abundance of monomethylarsonic acid

NCBI chr17:48,048,359...48,061,545
Ensembl chr17:48,048,329...48,061,545

G

NFE2 like bZIP transcription factor 2

decreases expression
multiple interactions

monomethylarsonic acid results in decreased expression of NFE2L2 mRNA
monomethylarsonic acid results in increased expression of and affects the localization of NFE2L2 protein; NFE2L2 mutant form inhibits the reaction [monomethylarsonic acid results in increased expression of NQO1 protein]

PMID:24091636 PMID:24161444

NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,218,667...177,392,756

G

nuclear factor, interleukin 3 regulated

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of NFIL3 mRNA

NCBI chr 9:91,409,045...91,483,497
Ensembl chr 9:91,409,045...91,423,832

G

nuclear factor kappa B subunit 1

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of NFKB1 mRNA

NCBI chr 4:102,501,359...102,617,302
Ensembl chr 4:102,501,330...102,617,302

G

niban apoptosis regulator 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of NIBAN3 mRNA

NCBI chr19:17,523,301...17,555,537
Ensembl chr19:17,523,301...17,553,839

G

NIPA like domain containing 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NIPAL4 mRNA

NCBI chr 5:157,460,213...157,474,722
Ensembl chr 5:157,460,213...157,474,722

G

NLR family pyrin domain containing 9

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of NLRP9B mRNA

NCBI chr19:55,708,438...55,738,402
Ensembl chr19:55,708,438...55,738,402

G

neuromedin U

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NMU mRNA

NCBI chr 4:55,595,231...55,636,793
Ensembl chr 4:55,595,229...55,636,698

G

nocturnin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of NOCT mRNA

NCBI chr 4:139,015,781...139,045,939
Ensembl chr 4:139,015,781...139,045,939

G

neuronal PAS domain protein 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of NPAS4 mRNA

NCBI chr11:66,409,158...66,426,707
Ensembl chr11:66,421,035...66,426,707

G

neuropeptide FF receptor 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NPFFR1 mRNA

NCBI chr10:70,247,329...70,284,004
Ensembl chr10:70,247,329...70,284,004

G

NAD(P)H quinone dehydrogenase 1

multiple interactions
increases expression

monomethylarsonic acid promotes the reaction [sulforaphane results in increased expression of and results in increased activity of NQO1 protein]; monomethylarsonic acid promotes the reaction [sulforaphane results in increased expression of NQO1 mRNA]; monomethylarsonic acid promotes the reaction [Tetrachlorodibenzodioxin results in increased activity of NQO1 protein]; monomethylarsonic acid promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of NQO1 mRNA]; monomethylarsonic acid results in increased expression of and results in increased activity of NQO1 protein; NFE2L2 mutant form inhibits the reaction [monomethylarsonic acid results in increased expression of NQO1 protein]
monomethylarsonic acid results in increased expression of NQO1 mRNA

NCBI chr16:69,709,401...69,726,560
Ensembl chr16:69,706,996...69,726,668

G

nuclear receptor subfamily 0 group B member 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of NR0B2 mRNA

NCBI chr 1:26,911,489...26,913,975
Ensembl chr 1:26,911,489...26,913,975

G

5'-nucleotidase ecto

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of NT5E mRNA

NCBI chr 6:85,450,083...85,495,784
Ensembl chr 6:85,449,584...85,495,791

G

nuclear GTPase, germinal center associated

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NUGGC mRNA

NCBI chr 8:28,021,964...28,083,936
Ensembl chr 8:28,021,964...28,083,936

G

neurexophilin and PC-esterase domain family member 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NXPE3 mRNA

NCBI chr 3:101,779,211...101,828,231
Ensembl chr 3:101,779,177...101,843,743

G

neurexophilin and PC-esterase domain family member 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NXPE4 mRNA

NCBI chr11:114,570,591...114,678,250
Ensembl chr11:114,570,591...114,595,786

G

nyctalopin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of NYX mRNA

NCBI chr X:41,447,343...41,475,652
Ensembl chr X:41,447,343...41,475,710

G

2'-5'-oligoadenylate synthetase 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of OAS2 mRNA

NCBI chr12:112,978,519...113,011,723
Ensembl chr12:112,978,395...113,011,723

G

8-oxoguanine DNA glycosylase

increases expression

monomethylarsonic acid results in increased expression of OGG1 mRNA

NCBI chr 3:9,749,952...9,783,108
Ensembl chr 3:9,749,944...9,788,219

G

olfactory receptor family 10 subfamily J member 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of OR10J2 mRNA

NCBI chr 1:159,397,465...159,440,967
Ensembl chr 1:159,437,845...159,443,078

G

odd-skipped related transciption factor 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of OSR2 mRNA

NCBI chr 8:98,944,442...98,952,100
Ensembl chr 8:98,944,403...98,952,104

G

P2Y receptor family member 10

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of P2RY10 mRNA

NCBI chr X:78,945,391...78,963,727
Ensembl chr X:78,945,332...78,963,727

G

prolyl 4-hydroxylase subunit alpha 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of P4HA1 mRNA

NCBI chr10:73,007,217...73,096,866
Ensembl chr10:73,007,217...73,096,974

G

parvin gamma

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PARVG mRNA

NCBI chr22:44,172,951...44,208,469
Ensembl chr22:44,172,956...44,219,533

G

paired box 5

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PAX5 mRNA

NCBI chr 9:36,833,269...37,034,268
Ensembl chr 9:36,833,269...37,034,268

G

paired box 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PAX6 mRNA

NCBI chr11:31,789,026...31,817,961
Ensembl chr11:31,784,779...31,817,961

G

protocadherin related 15

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PCDH15 mRNA

NCBI chr10:53,802,771...55,627,942
Ensembl chr10:53,802,771...55,627,942

G

protocadherin gamma subfamily B, 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PCDHGB1 mRNA

NCBI chr 5:141,350,099...141,512,975
Ensembl chr 5:141,350,099...141,512,975

G

PC-esterase domain containing 1B

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PCED1B mRNA

NCBI chr12:47,079,621...47,236,660
Ensembl chr12:47,079,603...47,236,662

G

proliferating cell nuclear antigen

increases expression

monomethylarsonic acid results in increased expression of PCNA mRNA

NCBI chr20:5,114,953...5,126,622
Ensembl chr20:5,114,953...5,126,626

G

proprotein convertase subtilisin/kexin type 9

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PCSK9 mRNA

NCBI chr 1:55,039,548...55,064,852
Ensembl chr 1:55,039,447...55,064,852

G

pleckstrin homology like domain family A member 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PHLDA1 mRNA

NCBI chr12:76,025,447...76,031,776
Ensembl chr12:76,025,447...76,031,776

G

paired like homeodomain 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PITX1 mRNA

NCBI chr 5:135,027,734...135,034,789
Ensembl chr 5:135,027,734...135,034,813

G

phospholipase A2 group IIA

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PLA2G2A mRNA

NCBI chr 1:19,975,431...19,980,434
Ensembl chr 1:19,975,431...19,980,416

G

phospholipase A2 group IID

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PLA2G2D mRNA

NCBI chr 1:20,111,939...20,119,536
Ensembl chr 1:20,111,939...20,119,566

G

phospholipase A2 group IVF

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PLA2G4F mRNA

NCBI chr15:42,139,034...42,156,636
Ensembl chr15:42,139,034...42,156,636

G

plasminogen activator, urokinase receptor

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PLAUR mRNA

NCBI chr19:43,646,095...43,670,169
Ensembl chr19:43,646,095...43,670,547

G

phospholipase B1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PLB1 mRNA

NCBI chr 2:28,496,060...28,644,142
Ensembl chr 2:28,457,145...28,644,142

G

phospholipase D family member 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PLD4 mRNA

NCBI chr14:104,924,879...104,937,785
Ensembl chr14:104,924,713...104,937,761

G

pleckstrin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PLEK mRNA

NCBI chr 2:68,365,282...68,397,453
Ensembl chr 2:68,365,282...68,397,453

G

pleckstrin homology and RhoGEF domain containing G4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PLEKHG4 mRNA

NCBI chr16:67,277,580...67,289,480
Ensembl chr16:67,277,510...67,289,499

G

placenta expressed transcript 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PLET1 mRNA

NCBI chr11:112,248,153...112,260,860
Ensembl chr11:112,248,153...112,260,860

G

polo like kinase 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PLK3 mRNA

NCBI chr 1:44,800,377...44,805,990
Ensembl chr 1:44,800,377...44,805,990

G

plexin C1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PLXNC1 mRNA

NCBI chr12:94,148,577...94,307,675
Ensembl chr12:94,148,577...94,307,675

G

phorbol-12-myristate-13-acetate-induced protein 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PMAIP1 mRNA

NCBI chr18:59,899,996...59,904,305
Ensembl chr18:59,899,996...59,904,305

G

patatin like phospholipase domain containing 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PNPLA1 mRNA

NCBI chr 6:36,243,168...36,313,955
Ensembl chr 6:36,243,203...36,313,955

G

patatin like phospholipase domain containing 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PNPLA3 mRNA

NCBI chr22:43,923,805...43,947,582
Ensembl chr22:43,923,792...43,964,488

G

POU class 2 homeobox associating factor 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of POU2AF1 mRNA

NCBI chr11:111,352,255...111,379,275
Ensembl chr11:111,352,255...111,455,630

G

POU class 2 homeobox 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of POU2F2 mRNA

NCBI chr19:42,086,110...42,197,936
Ensembl chr19:42,086,110...42,196,585

G

protein phosphatase 1 regulatory subunit 16B

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PPP1R16B mRNA

NCBI chr20:38,805,697...38,923,024
Ensembl chr20:38,805,697...38,923,024

G

protein kinase C alpha

increases expression

monomethylarsonic acid results in increased expression of PRKCA mRNA

NCBI chr17:66,302,613...66,810,743
Ensembl chr17:66,302,613...66,810,743

G

proline rich 5 like

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PRR5L mRNA

NCBI chr11:36,296,288...36,465,204
Ensembl chr11:36,296,288...36,465,204

G

serine protease 16

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PRSS16 mRNA

NCBI chr 6:27,247,701...27,256,620
Ensembl chr 6:27,247,701...27,256,624

G

phosphatase and tensin homolog

decreases expression

monomethylarsonic acid results in decreased expression of PTEN mRNA

NCBI chr10:87,863,625...87,971,930
Ensembl chr10:87,862,638...87,971,930

G

prostaglandin F receptor

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PTGFR mRNA

NCBI chr 1:78,490,974...78,540,701
Ensembl chr 1:78,303,884...78,540,701

G

protein tyrosine phosphatase non-receptor type 7

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PTPN7 mRNA

NCBI chr 1:202,147,013...202,161,588
Ensembl chr 1:202,147,013...202,161,588

G

protein tyrosine phosphatase receptor type C

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PTPRC mRNA

NCBI chr 1:198,638,713...198,757,476
Ensembl chr 1:198,638,457...198,757,476

G

protein tyrosine phosphatase receptor type C associated protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PTPRCAP mRNA

NCBI chr11:67,435,510...67,437,682
Ensembl chr11:67,435,510...67,437,682

G

pyroglutamylated RFamide peptide receptor

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of QRFPR mRNA

NCBI chr 4:121,328,642...121,381,018
Ensembl chr 4:121,328,642...121,381,059

G

RAB33A, member RAS oncogene family

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of RAB33A mRNA

NCBI chr X:130,110,623...130,184,870
Ensembl chr X:130,171,962...130,184,870

G

RAD51 paralog C

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of RAD51C mRNA

NCBI chr17:58,692,573...58,735,611
Ensembl chr17:58,692,573...58,735,611

G

RPA1 related single stranded DNA binding protein, X-linked

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of RADX mRNA

NCBI chr X:106,611,978...106,679,439
Ensembl chr X:106,611,930...106,679,439

G

Raf-1 proto-oncogene, serine/threonine kinase

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of RAF1 mRNA

NCBI chr 3:12,583,601...12,664,117
Ensembl chr 3:12,582,101...12,664,201

G

RAS protein activator like 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of RASAL3 mRNA

NCBI chr19:15,451,624...15,464,544
Ensembl chr19:15,451,624...15,464,544

G

ras related dexamethasone induced 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of RASD1 mRNA

NCBI chr17:17,494,437...17,496,395
Ensembl chr17:17,494,437...17,496,395

G

RAS guanyl releasing protein 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of RASGRP3 mRNA

NCBI chr 2:33,436,348...33,564,731
Ensembl chr 2:33,436,324...33,564,750

G

RAS like family 11 member A

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of RASL11A mRNA

NCBI chr13:27,270,830...27,275,192
Ensembl chr13:27,270,830...27,275,192

G

retinol dehydrogenase 16

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of RDH16 mRNA

NCBI chr12:56,951,431...56,957,608
Ensembl chr12:56,951,431...56,959,374

G

REC114 meiotic recombination protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of REC114 mRNA

NCBI chr15:73,443,164...73,560,013
Ensembl chr15:73,443,164...73,560,013

G

REC8 meiotic recombination protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of REC8 mRNA

NCBI chr14:24,172,080...24,180,923
Ensembl chr14:24,171,853...24,180,257

G

receptor accessory protein 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of REEP6 mRNA

NCBI chr19:1,491,181...1,497,927
Ensembl chr19:1,491,166...1,497,927

G

regenerating family member 1 beta

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of REG2 mRNA

NCBI chr 2:79,085,023...79,087,993
Ensembl chr 2:79,085,023...79,088,019

G

regenerating family member 3 alpha

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of REG3B mRNA

NCBI chr 2:79,157,006...79,159,753
Ensembl chr 2:79,157,003...79,159,753

G

regenerating family member 3 gamma

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of REG3G mRNA

NCBI chr 2:79,025,702...79,028,501
Ensembl chr 2:79,025,686...79,028,505

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of RELA mRNA

NCBI chr11:65,653,601...65,663,857
Ensembl chr11:65,653,599...65,663,090

G

RELT like 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of RELL2 mRNA

NCBI chr 5:141,636,997...141,641,064
Ensembl chr 5:141,636,950...141,641,064

G

ral guanine nucleotide dissociation stimulator like 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of RGL3 mRNA

NCBI chr19:11,394,060...11,419,314
Ensembl chr19:11,384,341...11,419,328

G

regulator of G protein signaling 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of RGS1 mRNA

NCBI chr 1:192,575,773...192,580,024
Ensembl chr 1:192,575,763...192,580,024

G

ras homolog family member H

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of RHOH mRNA

NCBI chr 4:40,191,080...40,246,967
Ensembl chr 4:40,191,011...40,246,967

G

receptor interacting serine/threonine kinase 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of RIPK3 mRNA

NCBI chr14:24,336,025...24,339,991
Ensembl chr14:24,336,025...24,340,022

G

RHO family interacting cell polarization regulator 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of RIPOR2 mRNA

NCBI chr 6:24,804,284...25,042,168
Ensembl chr 6:24,804,282...25,042,170

G

ribonuclease A family member k6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of RNASE6 mRNA

NCBI chr14:20,781,070...20,782,467
Ensembl chr14:20,781,268...20,782,467

G

ring finger protein 225

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of RNF225 mRNA

NCBI chr19:58,395,656...58,397,079
Ensembl chr19:58,395,656...58,397,079

G

ring finger protein 24

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of RNF24 mRNA

NCBI chr20:3,927,311...4,015,558
Ensembl chr20:3,927,309...4,015,558

G

ROS proto-oncogene 1, receptor tyrosine kinase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ROS1 mRNA

NCBI chr 6:117,287,353...117,425,942
Ensembl chr 6:117,287,353...117,425,942

G

ribonuclease P RNA component H1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of RPPH1 mRNA

NCBI chr14:20,343,071...20,343,411
Ensembl chr14:20,343,075...20,343,407

G

ribosomal protein S6 kinase related

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of RSKR mRNA

NCBI chr17:28,607,963...28,614,185
Ensembl chr17:28,455,752...28,614,197

G

rubicon like autophagy enhancer

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of RUBCNL mRNA

NCBI chr13:46,334,681...46,390,042
Ensembl chr13:46,334,681...46,438,190

G

ryanodine receptor 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of RYR1 mRNA

NCBI chr19:38,433,691...38,587,564
Ensembl chr19:38,433,691...38,595,273

G

ryanodine receptor 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of RYR3 mRNA

NCBI chr15:33,310,967...33,866,102
Ensembl chr15:33,310,962...33,866,121

G

S100 calcium binding protein G

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of S100G mRNA

NCBI chr X:16,650,158...16,654,670
Ensembl chr X:16,650,158...16,654,670

G

sphingosine-1-phosphate receptor 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of S1PR4 mRNA

NCBI chr19:3,178,769...3,180,332
Ensembl chr19:3,172,346...3,180,332

G

sacsin molecular chaperone

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SACS mRNA

NCBI chr13:23,328,830...23,433,702
Ensembl chr13:23,288,689...23,433,763

G

sterile alpha motif domain containing 4A

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SAMD4 mRNA

NCBI chr14:54,565,316...54,793,315
Ensembl chr14:54,566,117...54,793,315

G

SAM domain, SH3 domain and nuclear localization signals 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SAMSN1 mRNA

NCBI chr21:14,485,228...14,659,417
Ensembl chr21:14,485,228...14,658,821

G

SAM and SH3 domain containing 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SASH3 mRNA

NCBI chr X:129,779,949...129,795,201
Ensembl chr X:129,779,949...129,795,201

G

sciellin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SCEL mRNA

NCBI chr13:77,535,706...77,645,263
Ensembl chr13:77,535,674...77,645,263

G

sodium voltage-gated channel alpha subunit 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SCN4A mRNA

NCBI chr17:63,938,554...63,972,918
Ensembl chr17:63,938,554...63,972,918

G

secreted and transmembrane 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SECTM1A mRNA

NCBI chr17:82,321,024...82,333,959
Ensembl chr17:82,321,024...82,334,074

G

selectin L

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SELL mRNA

NCBI chr 1:169,690,667...169,711,620
Ensembl chr 1:169,690,665...169,711,702

G

semaphorin 7A (JohnMiltonHagen blood group)

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SEMA7A mRNA

NCBI chr15:74,409,289...74,433,958
Ensembl chr15:74,409,289...74,433,958

G

serpin family C member 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SERPINC1 mRNA

NCBI chr 1:173,903,800...173,917,327
Ensembl chr 1:173,903,800...173,917,327

G

serpin family F member 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SERPINF2 mRNA

NCBI chr17:1,742,871...1,755,265
Ensembl chr17:1,742,836...1,755,265

G

secreted frizzled related protein 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SFRP4 mRNA

NCBI chr 7:37,905,932...37,916,817
Ensembl chr 7:37,905,932...38,025,695

G

serum/glucocorticoid regulated kinase 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SGK1 mRNA

NCBI chr 6:134,169,256...134,318,112
Ensembl chr 6:134,169,248...134,318,112

G

SH3 domain containing 21

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SH3D21 mRNA

NCBI chr 1:36,306,368...36,330,236
Ensembl chr 1:36,306,368...36,329,340

G

shroom family member 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SHROOM4 mRNA

NCBI chr X:50,575,534...50,814,194
Ensembl chr X:50,586,796...50,814,302

G

sialic acid binding Ig like lectin 11

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SIGLECG mRNA

NCBI chr19:49,948,985...49,961,172
Ensembl chr19:49,948,985...49,961,172

G

signaling lymphocytic activation molecule family member 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLAMF1 mRNA

NCBI chr 1:160,608,106...160,647,044
Ensembl chr 1:160,608,106...160,647,044

G

SLAM family member 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLAMF6 mRNA

NCBI chr 1:160,485,036...160,523,255
Ensembl chr 1:160,485,030...160,523,262

G

SLAM family member 7

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLAMF7 mRNA

NCBI chr 1:160,739,057...160,754,821
Ensembl chr 1:160,739,057...160,754,821

G

solute carrier family 10 member 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SLC10A1 mRNA

NCBI chr14:69,775,416...69,797,241
Ensembl chr14:69,775,416...69,797,241

G

solute carrier family 10 member 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SLC10A6 mRNA

NCBI chr 4:86,823,468...86,849,384
Ensembl chr 4:86,823,468...86,849,384

G

solute carrier family 13 member 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLC13A1 mRNA

NCBI chr 7:123,113,531...123,199,971
Ensembl chr 7:123,113,531...123,199,972

G

solute carrier family 14 member 1 (Kidd blood group)

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLC14A1 mRNA

NCBI chr18:45,724,181...45,752,520
Ensembl chr18:45,687,025...45,752,520

G

solute carrier family 15 member 5

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SLC15A5 mRNA

NCBI chr12:16,188,485...16,277,685
Ensembl chr12:16,188,485...16,277,685

G

solute carrier family 16 member 8

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SLC16A8 mRNA

NCBI chr22:38,078,137...38,084,184
Ensembl chr22:38,078,134...38,084,184

G

solute carrier family 26 member 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SLC26A2 mRNA

NCBI chr 5:149,960,758...149,987,400
Ensembl chr 5:149,960,758...149,993,455

G

solute carrier family 27 member 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SLC27A3 mRNA

NCBI chr 1:153,775,407...153,780,157
Ensembl chr 1:153,774,354...153,780,157

G

solute carrier family 28 member 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLC28A2 mRNA

NCBI chr15:45,252,234...45,277,846
Ensembl chr15:45,252,234...45,277,846

G

solute carrier family 28 member 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLC28A3 mRNA

NCBI chr 9:84,275,457...84,368,727
Ensembl chr 9:84,275,457...84,340,758

G

solute carrier family 29 member 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLC29A4 mRNA

NCBI chr 7:5,282,943...5,306,912
Ensembl chr 7:5,274,369...5,306,912

G

solute carrier family 2 member 1

increases import

SLC2A1 protein results in increased import of monomethylarsonic acid

NCBI chr 1:42,925,353...42,958,868
Ensembl chr 1:42,925,353...42,958,893

G

solute carrier family 2 member 5

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLC2A5 mRNA

NCBI chr 1:9,035,106...9,094,195
Ensembl chr 1:9,035,106...9,088,478

G

solute carrier family 34 member 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SLC34A2 mRNA

NCBI chr 4:25,655,851...25,678,748
Ensembl chr 4:25,648,011...25,678,748

G

solute carrier family 38 member 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLC38A3 mRNA

NCBI chr 3:50,205,271...50,221,486
Ensembl chr 3:50,205,246...50,221,486

G

solute carrier family 38 member 8

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SLC38A8 mRNA

NCBI chr16:84,009,667...84,043,372
Ensembl chr16:84,009,667...84,042,795

G

solute carrier family 39 member 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SLC39A2 mRNA

NCBI chr14:20,999,293...21,001,871
Ensembl chr14:20,999,255...21,001,871

G

solute carrier family 41 member 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLC41A3 mRNA

NCBI chr 3:126,006,357...126,101,520
Ensembl chr 3:126,006,357...126,101,561

G

solute carrier family 5 member 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SLC5A3 mRNA

NCBI chr21:34,073,578...34,106,260
Ensembl chr21:34,073,578...34,106,260

G

solute carrier family 5 member 9

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLC5A9 mRNA

NCBI chr 1:48,222,716...48,248,638
Ensembl chr 1:48,222,685...48,248,644

G

solute carrier family 6 member 18

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SLC6A18 mRNA

NCBI chr 5:1,225,381...1,246,189
Ensembl chr 5:1,225,381...1,246,189

G

solute carrier family 7 member 9

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLC7A9 mRNA

NCBI chr19:32,830,511...32,869,767
Ensembl chr19:32,830,509...32,869,767

G

solute carrier family 8 member A3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLC8A3 mRNA

NCBI chr14:70,044,215...70,189,405
Ensembl chr14:70,044,215...70,189,480

G

solute carrier family 9 member A3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SLC9A3 mRNA

NCBI chr 5:470,456...524,449
Ensembl chr 5:470,456...524,449

G

solute carrier organic anion transporter family member 1B1

decreases abundance

SLCO1B1 gene SNP results in decreased abundance of monomethylarsonic acid

NCBI chr12:21,131,194...21,239,796
Ensembl chr12:21,131,194...21,239,796

G

solute carrier organic anion transporter family member 5A1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLCO5A1 mRNA

NCBI chr 8:69,667,046...69,834,978
Ensembl chr 8:69,667,046...69,834,978

G

stannin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SNN mRNA

NCBI chr16:11,668,455...11,679,152
Ensembl chr16:11,668,455...11,679,152

G

sterol O-acyltransferase 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SOAT2 mRNA

NCBI chr12:53,103,486...53,124,535
Ensembl chr12:53,103,486...53,124,535

G

superoxide dismutase 1

increases expression

monomethylarsonic acid results in increased expression of SOD1 mRNA

NCBI chr21:31,659,693...31,668,931
Ensembl chr21:31,659,666...31,668,931

G

superoxide dismutase 2

increases expression

monomethylarsonic acid results in increased expression of SOD2 mRNA

NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529

G

SOX1 overlapping transcript

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SOX1OT mRNA

NCBI chr13:111,972,310...112,108,015
Ensembl chr13:112,056,845...112,108,015

G

SP140 nuclear body protein like

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SP140 mRNA

NCBI chr 2:230,327,193...230,403,732
Ensembl chr 2:230,327,184...230,403,732

G

sperm associated antigen 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SPAG1 mRNA

NCBI chr 8:100,158,038...100,241,904
Ensembl chr 8:100,157,906...100,259,278

G

spermatogenesis associated 6 like

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SPATA6L mRNA

NCBI chr 9:4,588,821...4,666,480
Ensembl chr 9:4,553,386...4,666,674

G

spermatogenesis associated serine rich 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SPATS1 mRNA

NCBI chr 6:44,342,650...44,380,179
Ensembl chr 6:44,342,650...44,380,179

G

small proline rich protein 1A

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SPRR1A mRNA

NCBI chr 1:152,984,081...152,985,814
Ensembl chr 1:152,984,081...152,985,814

G

small proline rich protein 2A

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SPRR2H mRNA

NCBI chr 1:153,056,120...153,057,512
Ensembl chr 1:153,056,120...153,057,512

G

sprouty RTK signaling antagonist 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SPRY4 mRNA

NCBI chr 5:142,310,430...142,325,021
Ensembl chr 5:142,310,427...142,326,455

G

serine palmitoyltransferase small subunit B

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SPTSSB mRNA

NCBI chr 3:161,344,798...161,371,517
Ensembl chr 3:161,344,798...161,372,880

G

squalene epoxidase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SQLE mRNA

NCBI chr 8:124,998,505...125,022,283
Ensembl chr 8:124,998,497...125,022,283

G

SRC proto-oncogene, non-receptor tyrosine kinase

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of SRC mRNA

NCBI chr20:37,344,699...37,406,050
Ensembl chr20:37,344,685...37,406,050

G

sterol regulatory element binding transcription factor 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SREBF2 mRNA

NCBI chr22:41,833,105...41,907,305
Ensembl chr22:41,833,105...41,907,306

G

SRSF protein kinase 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SRPK3 mRNA

NCBI chr X:153,781,041...153,785,730
Ensembl chr X:153,776,412...153,785,732

G

ST3 beta-galactoside alpha-2,3-sialyltransferase 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ST3GAL4 mRNA

NCBI chr11:126,355,686...126,414,638
Ensembl chr11:126,355,640...126,440,344

G

ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ST6GALNAC3 mRNA

NCBI chr 1:76,074,746...76,637,339
Ensembl chr 1:76,074,746...76,634,603

G

ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ST8SIA4 mRNA

NCBI chr 5:100,806,933...100,903,282
Ensembl chr 5:100,806,933...100,903,282

G

ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ST8SIA6 mRNA

NCBI chr10:17,315,421...17,454,595
Ensembl chr10:17,315,421...17,454,595

G

signal transducing adaptor family member 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of STAP1 mRNA

NCBI chr 4:67,558,727...67,607,337
Ensembl chr 4:67,558,727...67,607,337

G

signal transducer and activator of transcription 3

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of STAT3 mRNA

NCBI chr17:42,313,324...42,388,442
Ensembl chr17:42,313,324...42,388,568

G

sushi domain containing 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SUSD3 mRNA

NCBI chr 9:93,058,701...93,085,133
Ensembl chr 9:93,058,688...93,085,133

G

synaptonemal complex protein 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SYCP2 mRNA

NCBI chr20:59,863,571...59,933,637
Ensembl chr20:59,863,564...59,933,655

G

synaptotagmin 5

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SYT5 mRNA

NCBI chr19:55,171,196...55,180,289
Ensembl chr19:55,171,196...55,180,289

G

synaptotagmin 8

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SYT8 mRNA

NCBI chr11:1,831,784...1,837,521
Ensembl chr11:1,828,307...1,837,521

G

TBC1 domain family member 10C

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TBC1D10C mRNA

NCBI chr11:67,403,913...67,410,090
Ensembl chr11:67,403,915...67,410,089

G

transcription factor 23

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TCF23 mRNA

NCBI chr 2:27,149,004...27,156,974
Ensembl chr 2:27,149,004...27,156,974

G

transcription factor 24

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TCF24 mRNA

NCBI chr 8:66,946,501...66,962,591
Ensembl chr 8:66,946,501...66,962,591

G

t-complex 10 like 2 (pseudogene)

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TCP10A mRNA

NCBI chr 6:167,170,619...167,196,751
Ensembl chr 6:167,172,145...167,196,679

G

terminal nucleotidyltransferase 5B

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TENT5B mRNA

NCBI chr 1:27,005,020...27,012,850
Ensembl chr 1:27,005,020...27,012,850

G

thymocyte expressed, positive selection associated 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TESPA1 mRNA

NCBI chr12:54,948,015...54,985,188
Ensembl chr12:54,948,015...54,984,762

G

transforming growth factor beta 1

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of TGFB1 mRNA

NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922

G

transforming growth factor beta receptor 2

increases expression

monomethylarsonic acid results in increased expression of TGFBR2 mRNA

NCBI chr 3:30,606,356...30,694,142
Ensembl chr 3:30,606,601...30,694,142

G

transglutaminase 7

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TGM7 mRNA

NCBI chr15:43,276,271...43,302,255
Ensembl chr15:43,276,271...43,302,255

G

thrombomodulin

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of THBD mRNA

NCBI chr20:23,045,633...23,049,672
Ensembl chr20:23,045,633...23,049,672

G

thymocyte selection associated

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of THEMIS mRNA

NCBI chr 6:127,696,628...127,918,595
Ensembl chr 6:127,708,072...127,918,631

G

TRAF interacting protein with forkhead associated domain

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TIFA mRNA

NCBI chr 4:112,274,537...112,285,904
Ensembl chr 4:112,272,968...112,285,955

G

toll like receptor 8

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TLR8 mRNA

NCBI chr X:12,906,620...12,923,169
Ensembl chr X:12,906,620...12,923,169

G

toll like receptor 9

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TLR9 mRNA

NCBI chr 3:52,221,080...52,225,645
Ensembl chr 3:52,221,080...52,225,645

G

transmembrane 4 L six family member 20

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TM4SF20 mRNA

NCBI chr 2:227,362,038...227,381,647
Ensembl chr 2:227,362,038...227,381,995

G

transmembrane p24 trafficking protein 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TMED6 mRNA

NCBI chr16:69,343,250...69,351,786
Ensembl chr16:69,343,250...69,351,786

G

transmembrane protein 140

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TMEM140 mRNA

NCBI chr 7:135,148,072...135,166,215
Ensembl chr 7:135,148,072...135,166,215

G

transmembrane protein 156

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TMEM156 mRNA

NCBI chr 4:38,966,744...39,032,409
Ensembl chr 4:38,966,744...39,032,922

G

transmembrane protein 17

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TMEM17 mRNA

NCBI chr 2:62,453,531...62,506,195
Ensembl chr 2:62,500,218...62,511,894

G

transmembrane protein 266

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TMEM266 mRNA

NCBI chr15:76,059,985...76,204,963
Ensembl chr15:76,059,958...76,229,121

G

transmembrane protein 71

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TMEM71 mRNA

NCBI chr 8:132,705,839...132,775,999
Ensembl chr 8:132,685,007...132,760,712

G

TNF receptor superfamily member 13B

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TNFRSF13B mRNA

NCBI chr17:16,939,081...16,972,118
Ensembl chr17:16,929,816...16,972,118

G

TNF receptor superfamily member 13C

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TNFRSF13C mRNA

NCBI chr22:41,922,032...41,926,806
Ensembl chr22:41,922,032...41,926,806

G

TNF receptor superfamily member 1A

decreases expression

monomethylarsonic acid results in decreased expression of TNFRSF1A mRNA

NCBI chr12:6,328,771...6,342,076
Ensembl chr12:6,328,757...6,342,114

G

TNF receptor superfamily member 25

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TNFRSF25 mRNA

NCBI chr 1:6,460,786...6,466,173
Ensembl chr 1:6,460,786...6,466,175

G

TNF superfamily member 11

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TNFSF11 mRNA

NCBI chr13:42,562,736...42,608,013
Ensembl chr13:42,562,736...42,608,013

G

TNF superfamily member 8

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TNFSF8 mRNA

NCBI chr 9:114,893,343...114,930,595
Ensembl chr 9:114,893,343...114,930,595

G

troponin I2, fast skeletal type

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TNNI2 mRNA

NCBI chr11:1,838,981...1,841,678
Ensembl chr11:1,838,981...1,841,680

G

troponin T3, fast skeletal type

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TNNT3 mRNA

NCBI chr11:1,919,552...1,938,702
Ensembl chr11:1,919,703...1,938,706

G

tumor protein p53

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of TP53 mRNA

NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,538

G

tubulin polymerization promoting protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TPPP mRNA

NCBI chr 5:659,862...700,727
Ensembl chr 5:659,862...693,352

G

transformer 2 alpha homolog

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TRA2A mRNA

NCBI chr 7:23,504,780...23,531,981
Ensembl chr 7:23,504,780...23,532,041

G

TNF receptor associated factor 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TRAF1 mRNA

NCBI chr 9:120,902,393...120,929,171
Ensembl chr 9:120,902,393...120,929,173

G

TNF receptor associated factor 3

decreases expression

monomethylarsonic acid results in decreased expression of TRAF3 mRNA

NCBI chr14:102,777,449...102,911,500
Ensembl chr14:102,777,449...102,911,500

G

TRAF3 interacting protein 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TRAF3IP3 mRNA

NCBI chr 1:209,756,053...209,782,310
Ensembl chr 1:209,756,032...209,782,320

G

tetratricopeptide repeat and ankyrin repeat containing 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TRANK1 mRNA

NCBI chr 3:36,826,819...36,945,744
Ensembl chr 3:36,826,819...36,945,057

G

T cell receptor associated transmembrane adaptor 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TRAT1 mRNA

NCBI chr 3:108,822,786...108,855,005
Ensembl chr 3:108,822,770...108,855,005

G

T cell receptor beta constant 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TRBC1 mRNA

NCBI chr 7:142,791,694...142,793,141
Ensembl chr 7:142,791,694...142,793,368

G

tripartite motif containing 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TRIM6 mRNA

NCBI chr11:5,596,111...5,612,952
Ensembl chr11:5,596,109...5,612,958

G

transient receptor potential cation channel subfamily C member 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TRPC3 mRNA

NCBI chr 4:121,874,481...121,952,060
Ensembl chr 4:121,874,481...121,952,060

G

transient receptor potential cation channel subfamily V member 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TRPV3 mRNA

NCBI chr17:3,510,502...3,557,812
Ensembl chr17:3,510,502...3,557,812

G

transient receptor potential cation channel subfamily V member 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TRPV6 mRNA

NCBI chr 7:142,871,208...142,885,745
Ensembl chr 7:142,871,208...142,885,745

G

tetraspanin 32

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TSPAN32 mRNA

NCBI chr11:2,302,013...2,318,204
Ensembl chr11:2,301,997...2,318,204

G

tetratricopeptide repeat domain 41, pseudogene

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TTC41 mRNA

NCBI chr12:103,843,749...103,930,211
Ensembl chr12:103,843,756...103,915,867

G

tubulin tyrosine ligase like 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TTLL2 mRNA

NCBI chr 6:167,325,086...167,342,688
Ensembl chr 6:167,325,071...167,359,503

G

tubulin tyrosine ligase like 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TTLL3 mRNA

NCBI chr 3:9,809,727...9,836,365
Ensembl chr 3:9,808,086...9,855,138

G

tubulin tyrosine ligase like 9

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TTLL9 mRNA

NCBI chr20:31,870,634...31,945,000
Ensembl chr20:31,870,634...31,945,000

G

tweety family member 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TTYH3 mRNA

NCBI chr 7:2,631,986...2,664,802
Ensembl chr 7:2,631,961...2,664,802

G

TXK tyrosine kinase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TXK mRNA

NCBI chr 4:48,066,393...48,134,250
Ensembl chr 4:48,066,393...48,134,250

G

thioredoxin

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of TXN mRNA

NCBI chr 9:110,243,810...110,256,507
Ensembl chr 9:110,243,810...110,256,507

G

thioredoxin reductase 1

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of TXNRD1 mRNA

NCBI chr12:104,215,779...104,350,307
Ensembl chr12:104,215,779...104,350,307

G

uncoupling protein 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of UCP2 mRNA

NCBI chr11:73,974,672...73,983,202
Ensembl chr11:73,974,672...73,982,843

G

UDP glucuronosyltransferase family 1 member A3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of UGT1A2 mRNA

NCBI chr 2:233,729,042...233,773,300
Ensembl chr 2:233,729,042...233,773,300

G

UDP glucuronosyltransferase family 1 member A4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of UGT1A5 mRNA

NCBI chr 2:233,718,736...233,773,300
Ensembl chr 2:233,718,736...233,773,300

G

UL16 binding protein 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ULBP1 mRNA

NCBI chr 6:149,963,943...149,973,715
Ensembl chr 6:149,963,943...149,973,715

G

vascular cell adhesion molecule 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of VCAM1 mRNA

NCBI chr 1:100,719,742...100,739,045
Ensembl chr 1:100,719,742...100,739,045

G

vascular endothelial growth factor A

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of VEGFA mRNA

NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487

G

vanin 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of VNN1 mRNA

NCBI chr 6:132,680,849...132,714,055
Ensembl chr 6:132,680,849...132,714,055

G

V-set pre-B cell surrogate light chain 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of VPREB3 mRNA

NCBI chr22:23,752,743...23,754,425
Ensembl chr22:23,752,743...23,754,425

G

vacuolar protein sorting 25 homolog

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of VPS25 mRNA

NCBI chr17:42,773,449...42,779,599
Ensembl chr17:42,773,449...42,779,599

G

WASP actin nucleation promoting factor

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of WAS mRNA

NCBI chr X:48,676,636...48,691,427
Ensembl chr X:48,676,596...48,691,431

G

WDFY family member 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of WDFY4 mRNA

NCBI chr10:48,684,873...48,982,956
Ensembl chr10:48,684,873...48,982,956

G

WD repeat domain 31

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of WDR31 mRNA

NCBI chr 9:113,313,222...113,340,275
Ensembl chr 9:113,313,222...113,340,298

G

WD repeat domain 54

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of WDR54 mRNA

NCBI chr 2:74,421,730...74,425,755
Ensembl chr 2:74,421,678...74,425,755

G

Wnt family member 1

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of WNT1 mRNA

NCBI chr12:48,978,322...48,982,620
Ensembl chr12:48,978,322...48,982,620

G

XK related 8

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of XKR8 mRNA

NCBI chr 1:27,959,973...27,968,093
Ensembl chr 1:27,959,588...27,968,093

G

X-prolyl aminopeptidase 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of XPNPEP2 mRNA

NCBI chr X:129,738,979...129,769,536
Ensembl chr X:129,738,949...129,769,536

G

zeta chain of T cell receptor associated protein kinase 70

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ZAP70 mRNA

NCBI chr 2:97,713,576...97,756,364
Ensembl chr 2:97,713,576...97,739,862

G

zinc finger and BTB domain containing 16

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ZBTB16 mRNA

NCBI chr11:114,059,711...114,256,770
Ensembl chr11:114,059,041...114,256,765

G

zinc finger and BTB domain containing 40

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ZBTB40 mRNA

NCBI chr 1:22,428,909...22,531,154
Ensembl chr 1:22,428,838...22,531,157

G

zinc finger CCCH-type containing 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ZC3H6 mRNA

NCBI chr 2:112,275,597...112,340,059
Ensembl chr 2:112,275,597...112,340,059

G

zinc finger DHHC-type palmitoyltransferase 19

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ZDHHC19 mRNA

NCBI chr 3:196,197,452...196,211,400
Ensembl chr 3:196,197,452...196,211,437

G

zinc finger homeobox 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ZFHX2 mRNA

NCBI chr14:23,520,857...23,555,952
Ensembl chr14:23,520,857...23,556,192

G

ZFP92 zinc finger protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ZFP92 mRNA

NCBI chr X:153,411,472...153,426,481
Ensembl chr X:153,411,472...153,426,481

G

zinc finger matrin-type 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ZMAT4 mRNA

NCBI chr 8:40,530,590...40,897,826
Ensembl chr 8:40,530,590...40,897,833

G

zinc finger protein 419

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ZFP773 mRNA

NCBI chr19:57,487,750...57,496,098
Ensembl chr19:57,487,711...57,496,098

G

zinc finger protein 503

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ZFP503 mRNA

NCBI chr10:75,279,725...75,401,916
Ensembl chr10:75,397,830...75,401,764

G

zinc finger protein 831

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ZFP831 mRNA

NCBI chr20:59,123,388...59,259,113
Ensembl chr20:59,123,381...59,259,113

phenylarsonic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

glutaminase

decreases expression
decreases activity

benzenearsonic acid results in decreased expression of GLS protein
benzenearsonic acid results in decreased activity of GLS protein

NCBI chr 2:190,880,821...190,965,552
Ensembl chr 2:190,880,821...190,965,552

G

heme oxygenase 1

increases expression

benzenearsonic acid results in increased expression of HMOX1 mRNA

NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214

roxarsone

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiopoietin 1

decreases expression

Roxarsone results in decreased expression of ANGPT1 mRNA

NCBI chr 8:107,249,482...107,497,918
Ensembl chr 8:107,249,482...107,498,055

G

chondromodulin

decreases expression

Roxarsone results in decreased expression of CNMD mRNA

NCBI chr13:52,703,264...52,739,820
Ensembl chr13:52,703,264...52,739,820

G

C-X-C motif chemokine ligand 9

decreases expression

Roxarsone results in decreased expression of CXCL9 mRNA

NCBI chr 4:76,001,275...76,007,509
Ensembl chr 4:76,001,275...76,007,509

G

ectonucleotide pyrophosphatase/phosphodiesterase 2

increases secretion

Roxarsone results in increased secretion of ENPP2 protein

NCBI chr 8:119,557,086...119,673,390
Ensembl chr 8:119,557,086...119,673,453

G

FH2 domain containing 1

decreases expression

Roxarsone results in decreased expression of INF1 mRNA

NCBI chr 4:152,911,339...152,979,671
Ensembl chr 4:152,936,323...152,979,671

G

hepatocyte growth factor

increases expression

Roxarsone results in increased expression of HGF mRNA

NCBI chr 7:81,699,010...81,770,047
Ensembl chr 7:81,699,010...81,770,438

G

leptin

decreases expression

Roxarsone results in decreased expression of LEP mRNA

NCBI chr 7:128,241,278...128,257,629
Ensembl chr 7:128,241,278...128,257,629

G

matrix metallopeptidase 9

increases expression

Roxarsone results in increased expression of MMP9 mRNA; Roxarsone results in increased expression of MMP9 protein

NCBI chr20:46,008,908...46,016,561
Ensembl chr20:46,008,908...46,016,561

G

mechanistic target of rapamycin kinase

multiple interactions
increases expression

Roxarsone results in increased expression of and results in increased phosphorylation of MTOR protein; Sirolimus inhibits the reaction [Roxarsone results in increased expression of and results in increased phosphorylation of MTOR protein]
Roxarsone results in increased expression of MTOR mRNA

NCBI chr 1:11,106,535...11,262,551
Ensembl chr 1:11,106,535...11,262,556

G

nitric oxide synthase 3

multiple interactions

Roxarsone results in increased phosphorylation of and results in increased activity of NOS3 protein

NCBI chr 7:150,991,017...151,014,588
Ensembl chr 7:150,991,017...151,014,588

G

platelet and endothelial cell adhesion molecule 1

increases expression
multiple interactions

Roxarsone results in increased expression of PECAM1 protein
Semaxinib inhibits the reaction [Roxarsone results in increased expression of PECAM1 protein]

NCBI chr17:64,319,415...64,390,860
Ensembl chr17:64,319,415...64,413,776

G

plasminogen

decreases expression

Roxarsone results in decreased expression of PLG mRNA

NCBI chr 6:160,702,193...160,754,097
Ensembl chr 6:160,702,194...160,754,097

G

ribosomal protein S6 kinase B1

multiple interactions
increases expression

Roxarsone results in increased expression of and results in increased phosphorylation of RPS6KB1 protein; Sirolimus inhibits the reaction [Roxarsone results in increased expression of and results in increased phosphorylation of RPS6KB1 protein]
Roxarsone results in increased expression of RPS6KB1 mRNA

NCBI chr17:59,893,121...59,950,574
Ensembl chr17:59,893,046...59,950,574

G

vascular endothelial growth factor A

multiple interactions

Roxarsone results in increased expression of and results in increased secretion of VEGFA protein

NCBI chr 6:43,770,211...43,786,487
Ensembl chr 6:43,770,184...43,786,487

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	26034
chemical entity	26024
atom	26009
metalloid atom	16404
arsenic atom	15087
arsenic molecular entity	15097
arsenic oxoacid	4441
arsonic acids	656
arsonic acid	656
arsonoyl group	0
organoarsonic acid +	654
Path 2
Term	Annotations
CHEBI ontology	26034
subatomic particle	26009
composite particle	26009
hadron	26020
baryon	26009
nucleon	26009
atomic nucleus	26009
atom	26009
main group element atom	25834
p-block element atom	25834
chalcogen	24917
oxygen atom	24817
oxygen molecular entity	24806
hydroxides	24049
oxoacid	22975
pnictogen oxoacid	13799
arsenic oxoacid	4441
arsonic acids	656
arsonic acid	656
arsonoyl group	0
organoarsonic acid +	654

paths to the root